fbpx
Wikipedia

Kidney stone disease

January 01, 1970

Kidney stone disease, also known as renal calculus disease, nephrolithiasis or urolithiasis, is a crystallopathy where a solid piece of material (renal calculus) develops in the urinary tract.[2] Renal calculi typically form in the kidney and leave the body in the urine stream.[2] A small calculus may pass without causing symptoms.[2] If a stone grows to more than 5 millimeters (0.2 inches), it can cause blockage of the ureter, resulting in sharp and severe pain in the lower back that often radiates downward to the groin (renal colic).[2][7] A calculus may also result in blood in the urine, vomiting, or painful urination.[2] About half of people who have had a renal calculus are likely to have another within ten years.[8]

Kidney stone disease
Other namesUrolithiasis, kidney stone, renal calculus, nephrolith, kidney stone disease,[1]
A kidney stone, 8 millimeters (0.3 in) in diameter
SpecialtyUrology, nephrology
SymptomsSevere pain in the lower back or abdomen, blood in the urine, vomiting, nausea[2]
CausesGenetic and environmental factors[2]
Diagnostic methodBased on symptoms, urine testing, medical imaging[2]
Differential diagnosisAbdominal aortic aneurysm, diverticulitis, appendicitis, pyelonephritis[3]
PreventionDrinking fluids such that more than two liters of urine are produced per day[4]
TreatmentPain medication, extracorporeal shock wave lithotripsy, ureteroscopy, percutaneous nephrolithotomy[2]
Frequency22.1 million (2015)[5]
Deaths16,100 (2015)[6]

Most calculi form by a combination of genetics and environmental factors.[2] Risk factors include high urine calcium levels, obesity, certain foods, some medications, calcium supplements, hyperparathyroidism, gout and not drinking enough fluids.[2][8] Calculi form in the kidney when minerals in urine are at high concentration.[2] The diagnosis is usually based on symptoms, urine testing, and medical imaging.[2] Blood tests may also be useful.[2] Calculi are typically classified by their location: nephrolithiasis (in the kidney), ureterolithiasis (in the ureter), cystolithiasis (in the bladder), or by what they are made of (calcium oxalate, uric acid, struvite, cystine).[2]

In those who have had renal calculi, drinking fluids is a way to prevent them. Drinking fluids such that more than two liters of urine are produced per day is recommended.[4] If fluid intake alone is not effective to prevent renal calculi, the medications thiazide diuretic, citrate, or allopurinol may be suggested.[4] Soft drinks containing phosphoric acid (typically colas) should be avoided.[4] When a calculus causes no symptoms, no treatment is needed.[2] For those with symptoms, pain control is usually the first measure, using medications such as nonsteroidal anti-inflammatory drugs or opioids.[7][9] Larger calculi may be helped to pass with the medication tamsulosin[10] or may require procedures such as extracorporeal shock wave lithotripsy, ureteroscopy, or percutaneous nephrolithotomy.[2]

Renal calculi have affected humans throughout history with a description of surgery to remove them dating from as early as 600 BC in ancient India by Sushruta.[1] Between 1% and 15% of people globally are affected by renal calculi at some point in their lives.[8][11] In 2015, 22.1 million cases occurred,[5] resulting in about 16,100 deaths.[6] They have become more common in the Western world since the 1970s.[8][12] Generally, more men are affected than women.[2][11] The prevalence and incidence of the disease rises worldwide and continues to be challenging for patients, physicians, and healthcare systems alike. In this context, epidemiological studies are striving to elucidate the worldwide changes in the patterns and the burden of the disease and identify modifiable risk factors that contribute to the development of renal calculi.[13]

Signs and symptoms edit

 
Diagram showing the typical location of renal colic, below the rib cage to just above the pelvis

The hallmark of a stone that obstructs the ureter or renal pelvis is excruciating, intermittent pain that radiates from the flank to the groin or to the inner thigh.[14] This is due to the transfer of referred pain signals from the lower thoracic splanchnic nerves to the lumbar splanchnic nerves as the stone passes down from the kidney or proximal ureter to the distal ureter. This pain, known as renal colic, is often described as one of the strongest pain sensations known.[15] Renal colic caused by kidney stones is commonly accompanied by urinary urgency, restlessness, hematuria, sweating, nausea, and vomiting. It typically comes in waves lasting 20 to 60 minutes caused by peristaltic contractions of the ureter as it attempts to expel the stone.[14]

The embryological link between the urinary tract, the genital system, and the gastrointestinal tract is the basis of the radiation of pain to the gonads, as well as the nausea and vomiting that are also common in urolithiasis.[16] Postrenal azotemia and hydronephrosis can be observed following the obstruction of urine flow through one or both ureters.[17]

Pain in the lower-left quadrant can sometimes be confused with diverticulitis because the sigmoid colon overlaps the ureter, and the exact location of the pain may be difficult to isolate due to the proximity of these two structures.

Risk factors edit

Dehydration from low fluid intake is a major factor in stone formation.[14][18] Individuals living in warm climates are at higher risk due to increased fluid loss.[19] Obesity, immobility, and sedentary lifestyles are other leading risk factors.[19]

High dietary intake of animal protein,[14] sodium, sugars including honey, refined sugars, fructose and high fructose corn syrup,[20] and excessive consumption of fruit juices may increase the risk of kidney stone formation due to increased uric acid excretion and elevated urinary oxalate levels (whereas tea, coffee, wine and beer may decrease the risk).[19][18]

Kidney stones can result from an underlying metabolic condition, such as distal renal tubular acidosis,[21] Dent's disease,[22] hyperparathyroidism,[23] primary hyperoxaluria,[24] or medullary sponge kidney. 3–20% of people who form kidney stones have medullary sponge kidney.[25][26]

Kidney stones are more common in people with Crohn's disease;[27] Crohn's disease is associated with hyperoxaluria and malabsorption of magnesium.[28]

A person with recurrent kidney stones may be screened for such disorders. This is typically done with a 24-hour urine collection. The urine is analyzed for features that promote stone formation.[17]

Calcium oxalate edit

 
A kidney stone (yellow) composed of calcium oxalate

Calcium is one component of the most common type of human kidney stones, calcium oxalate. Some studies suggest that people who take calcium or vitamin D as a dietary supplement have a higher risk of developing kidney stones.[29][30] In the United States, kidney stone formation was used as an indicator of excess calcium intake by the Reference Daily Intake committee for calcium in adults.[31]

In the early 1990s, a study conducted for the Women's Health Initiative in the US found that postmenopausal women who consumed 1000 mg of supplemental calcium and 400 international units of vitamin D per day for seven years had a 17% higher risk of developing kidney stones than subjects taking a placebo.[29] The Nurses' Health Study also showed an association between supplemental calcium intake and kidney stone formation.[30]

Unlike supplemental calcium, high intakes of dietary calcium do not appear to cause kidney stones and may actually protect against their development.[30][29] This is perhaps related to the role of calcium in binding ingested oxalate in the gastrointestinal tract. As the amount of calcium intake decreases, the amount of oxalate available for absorption into the bloodstream increases; this oxalate is then excreted in greater amounts into the urine by the kidneys. In the urine, oxalate is a very strong promoter of calcium oxalate precipitation—about 15 times stronger than calcium.

A 2004 study found that diets low in calcium are associated with a higher overall risk for kidney stone formation.[32] For most individuals, other risk factors for kidney stones, such as high intakes of dietary oxalates and low fluid intake, play a greater role than calcium intake.[33]

Other electrolytes edit

Calcium is not the only electrolyte that influences the formation of kidney stones. For example, by increasing urinary calcium excretion, high dietary sodium may increase the risk of stone formation.[30]

Drinking fluoridated tap water may increase the risk of kidney stone formation by a similar mechanism, though further epidemiologic studies are warranted to determine whether fluoride in drinking water is associated with an increased incidence of kidney stones.[34] High dietary intake of potassium appears to reduce the risk of stone formation because potassium promotes the urinary excretion of citrate, an inhibitor of calcium crystal formation.[35]

Kidney stones are more likely to develop, and to grow larger, if a person has low dietary magnesium. Magnesium inhibits stone formation.[36]

Animal protein edit

Diets in Western nations typically contain a large proportion of animal protein. Eating animal protein creates an acid load that increases urinary excretion of calcium and uric acid and reduced citrate. Urinary excretion of excess sulfurous amino acids (e.g., cysteine and methionine), uric acid, and other acidic metabolites from animal protein acidifies the urine, which promotes the formation of kidney stones.[37] Low urinary-citrate excretion is also commonly found in those with a high dietary intake of animal protein, whereas vegetarians tend to have higher levels of citrate excretion.[30] Low urinary citrate, too, promotes stone formation.[37]

Vitamins edit

The evidence linking vitamin C supplements with an increased rate of kidney stones is inconclusive.[38][39] The excess dietary intake of vitamin C might increase the risk of calcium-oxalate stone formation.[40] The link between vitamin D intake and kidney stones is also tenuous.

Excessive vitamin D supplementation may increase the risk of stone formation by increasing the intestinal absorption of calcium; correction of a deficiency does not.[30]

Pathophysiology edit

 
Small crystals formed in the kidney. The most common crystals are made of calcium oxalate and they are generally 4–5 mm. Staghorn kidney stones are considerably larger. 1. Calcium and oxalate come together to make the crystal nucleus. Supersaturation promotes their combination (as does inhibition.) 2. Continued deposition at the renal papillae leads to the growth of the kidney stones. 3. Kidney stones grow and collect debris. In the case where the kidney stones block all routes to the renal papillae, this can cause extreme discomfort and pain. 4. The complete staghorn stone forms and retention occurs. Smaller solids that break off can become trapped in the urinary glands causing discomfort. 5. Displaced stones travel through the ureter. If they cannot be broken down, they must be physically removed by a surgeon.

Supersaturation of urine edit

When the urine becomes supersaturated (when the urine solvent contains more solutes than it can hold in solution) with one or more calculogenic (crystal-forming) substances, a seed crystal may form through the process of nucleation.[25] Heterogeneous nucleation (where there is a solid surface present on which a crystal can grow) proceeds more rapidly than homogeneous nucleation (where a crystal must grow in a liquid medium with no such surface), because it requires less energy. Adhering to cells on the surface of a renal papilla, a seed crystal can grow and aggregate into an organized mass. Depending on the chemical composition of the crystal, the stone-forming process may proceed more rapidly when the urine pH is unusually high or low.[41]

Supersaturation of the urine with respect to a calculogenic compound is pH-dependent. For example, at a pH of 7.0, the solubility of uric acid in urine is 158 mg/100 mL. Reducing the pH to 5.0 decreases the solubility of uric acid to less than 8 mg/100 mL. The formation of uric-acid stones requires a combination of hyperuricosuria (high urine uric-acid levels) and low urine pH; hyperuricosuria alone is not associated with uric-acid stone formation if the urine pH is alkaline.[42] Supersaturation of the urine is a necessary, but not a sufficient, condition for the development of any urinary calculus.[25] Supersaturation is likely the underlying cause of uric acid and cystine stones, but calcium-based stones (especially calcium oxalate stones) may have a more complex cause.[43]

Randall's plaque edit

While supersaturation of urine may lead to crystalluria, it does not necessarily promote the formation of a kidney stone because the particle may not reach the sufficient size needed for renal attachment.[44][45] On the other hand, Randall's plaques, which were first identified by Alexander Randall in 1937,[46] are calcium phosphate deposits that form in the papillary interstitium and are thought to be the nidus required for stone development.[47] In addition to Randall's plugs, which form in the Duct of Bellini, these structures can generate reactive oxygen species that further enhance stone formation.[48]

Pathogenic bacteria edit

Some bacteria have roles in promoting stone formation. Specifically, urease-positive bacteria, such as Proteus mirabilis can produce the enzyme urease, which converts urea to ammonia and carbon dioxide.[49] This increases the urinary pH and promotes struvite stone formation. Additionally, non-urease producing bacteria can provide bacteria components that can promote calcium oxalate crystallization, though this mechanism is poorly understood.[50][51]

Inhibitors of stone formation edit

Normal urine contains chelating agents, such as citrate, that inhibit the nucleation, growth, and aggregation of calcium-containing crystals. Other endogenous inhibitors include calgranulin (an S-100 calcium-binding protein), Tamm–Horsfall protein, glycosaminoglycans, uropontin (a form of osteopontin), nephrocalcin (an acidic glycoprotein), prothrombin F1 peptide, and bikunin (uronic acid-rich protein). The biochemical mechanisms of action of these substances have not yet been thoroughly elucidated. However, when these substances fall below their normal proportions, stones can form from an aggregation of crystals.[52]

Sufficient dietary intake of magnesium and citrate inhibits the formation of calcium oxalate and calcium phosphate stones; in addition, magnesium and citrate operate synergistically to inhibit kidney stones. The efficacy of magnesium in subduing stone formation and growth is dose-dependent.[30][36][53]

Hypocitraturia edit

Hypocitraturia or low urinary-citrate excretion (variably defined as less than 320 mg/day) can be a contributing cause of kidney stones in up to 2/3 of cases. The protective role of citrate is linked to several mechanisms; citrate reduces urinary supersaturation of calcium salts by forming soluble complexes with calcium ions and by inhibiting crystal growth and aggregation. Therapy with potassium citrate is commonly prescribed in clinical practice to increase urinary citrate and to reduce stone formation rates. Alkali citrate is also used to increase urine citrate levels. It can be prescribed or found over-the-counter in pill, liquid or powder form.[54][55]

Diagnosis edit

Diagnosis of kidney stones is made on the basis of information obtained from the history, physical examination, urinalysis, and radiographic studies.[56] Clinical diagnosis is usually made on the basis of the location and severity of the pain, which is typically colicky in nature (comes and goes in spasmodic waves). Pain in the back occurs when calculi produce an obstruction in the kidney.[57] Physical examination may reveal fever and tenderness at the costovertebral angle on the affected side.[56]

Imaging studies edit

Calcium-containing stones are relatively radiodense (opaque to X-rays), and they can often be detected by a traditional radiography of the abdomen that includes the kidneys, ureters, and bladder (KUB film[clarification needed]).[58] KUB[clarification needed] radiography, although useful in monitoring size of stone or passage of stone in stone formers, might not be useful in the acute setting due to low sensitivity.[59] Some 60% of all renal stones are radiopaque.[60][61] In general, calcium phosphate stones have the greatest density, followed by calcium oxalate and magnesium ammonium phosphate stones. Cystine calculi are only faintly radiodense, while uric acid stones are usually entirely radiolucent.[62]

In people with a history of stones, those who are less than 50 years of age and are presenting with the symptoms of stones without any concerning signs do not require helical CT scan imaging.[63] A computed tomography (CT) scan is also not typically recommended in children.[64]

Otherwise a noncontrast helical CT scan with 5 millimeters (0.2 in) sections is the diagnostic method to use to detect kidney stones and confirm the diagnosis of kidney stone disease.[16][56][60][65][7] Near all stones are detectable on CT scans with the exception of those composed of certain drug residues in the urine,[58] such as from indinavir.

Where a CT scan is unavailable, an intravenous pyelogram may be performed to help confirm the diagnosis of urolithiasis. This involves intravenous injection of a contrast agent followed by a KUB film. Uroliths present in the kidneys, ureters, or bladder may be better defined by the use of this contrast agent. Stones can also be detected by a retrograde pyelogram, where a similar contrast agent is injected directly into the distal ostium of the ureter (where the ureter terminates as it enters the bladder).[60]

Renal ultrasonography can sometimes be useful, because it gives details about the presence of hydronephrosis, suggesting that the stone is blocking the outflow of urine.[58] Radiolucent stones, which do not appear on KUB, may show up on ultrasound imaging studies. Other advantages of renal ultrasonography include its low cost and absence of radiation exposure. Ultrasound imaging is useful for detecting stones in situations where X-rays or CT scans are discouraged, such as in children or pregnant women.[66] Despite these advantages, renal ultrasonography in 2009 was not considered a substitute for noncontrast helical CT scan in the initial diagnostic evaluation of urolithiasis.[65] The main reason for this is that, compared with CT, renal ultrasonography more often fails to detect small stones (especially ureteral stones) and other serious disorders that could be causing the symptoms.[14]

On the contrary, a 2014 study suggested that ultrasonography should be used as the initial diagnostic imaging test, with further imaging studies be performed at the discretion of the physician on the basis of clinical judgment, and using ultrasonography rather than CT as an initial diagnostic test results in less radiation exposure and equally good outcome.[67]

  •  
    Bilateral kidney stones can be seen on this KUB radiograph. There are phleboliths in the pelvis, which can be misinterpreted as bladder stones.
  •  
    Axial CT scan of abdomen without contrast, showing a 3-mm stone (marked by an arrow) in the left proximal ureter
  •  
    Renal ultrasonograph of a stone located at the pyeloureteric junction with accompanying hydronephrosis.
  •  
    Measurement of a 5.6 mm large kidney stone in soft tissue versus skeletal CT window.

Laboratory examination edit

 
Struvite crystals found on microscopic examination of the urine

Laboratory investigations typically carried out include:[56][65][58][68]

  • microscopic examination of the urine, which may show red blood cells, bacteria, leukocytes, urinary casts, and crystals;
  • urine culture to identify any infecting organisms present in the urinary tract and sensitivity to determine the susceptibility of these organisms to specific antibiotics;
  • complete blood count, looking for neutrophilia (increased neutrophil granulocyte count) suggestive of bacterial infection, as seen in the setting of struvite stones;
  • renal function tests to look for abnormally high blood calcium levels (hypercalcemia);
  • 24 hour urine collection to measure total daily urinary volume, magnesium, sodium, uric acid, calcium, citrate, oxalate, and phosphate;
  • collection of stones (by urinating through a StoneScreen kidney stone collection cup or a simple tea strainer) is useful. Chemical analysis of collected stones can establish their composition, which in turn can help to guide future preventive and therapeutic management.

Composition edit

Kidney stone type Relative incidence (adults)[69] Circumstances Color and microscopy appearance Radio-density Details
Calcium oxalate 60% when urine is acidic (decreased pH)[70] Black/dark brown
 
 Radio-opaque Some of the oxalate in urine is produced by the body. Calcium and oxalate in the diet play a part but are not the only factors that affect the formation of calcium oxalate stones. Dietary oxalate is found in many vegetables, fruits, and nuts. Calcium from bone may also play a role in kidney stone formation.
Calcium phosphate 10-20% when urine is alkaline (high pH) Dirty white
 
 Radio-opaque Tends to grow in alkaline urine especially when Proteus bacteria are present. The most common type among pregnant women.[69]
Uric acid 10-20% when urine is persistently acidic Yellow/reddish brown
 
 Radiolucent Diets rich in animal proteins and purines: substances found naturally in all food but especially in organ meats, fish, and shellfish.
Struvite 3% infections in the kidney and when urine is alkaline (high pH) Dirty white
 
 Radio-opaque Prevention of struvite stones depends on staying infection-free. Diet has not been shown to affect struvite stone formation.
Cystine 1–2%[71] rare genetic disorder Pink/yellow
 
 Radio-opaque Cystine, an amino acid (a dimer of cysteine, of the building blocks of protein), leaks through the kidneys and into the urine to form crystals.
Xanthine[72] extremely rare Brick red Radiolucent
 
Scanning electron micrograph of the surface of a kidney stone showing tetragonal crystals of weddellite (calcium oxalate dihydrate) emerging from the amorphous central part of the stone (the horizontal length of the picture represents 0.5 mm of the figured original)
 
Multiple kidney stones composed of uric acid and a small amount of calcium oxalate
 
A lenticular kidney stone, excreted in the urine

Calcium-containing stones edit

By far, the most common type of kidney stones worldwide contains calcium. For example, calcium-containing stones represent about 80% of all cases in the United States; these typically contain calcium oxalate either alone or in combination with calcium phosphate in the form of apatite or brushite.[25][52] Factors that promote the precipitation of oxalate crystals in the urine, such as primary hyperoxaluria, are associated with the development of calcium oxalate stones.[24] The formation of calcium phosphate stones is associated with conditions such as hyperparathyroidism[23] and renal tubular acidosis.[73]

Oxaluria is increased in patients with certain gastrointestinal disorders including inflammatory bowel disease such as Crohn's disease or in patients who have undergone resection of the small bowel or small-bowel bypass procedures. Oxaluria is also increased in patients who consume increased amounts of oxalate (found in vegetables and nuts). Primary hyperoxaluria is a rare autosomal recessive condition that usually presents in childhood.[74]

Calcium oxalate crystals can come in two varieties. Calcium oxalate monohydrate can appear as 'dumbbells' or as long ovals that resemble the individual posts in a picket fence. Calcium oxalate dihydrate have a tetragonal “envelope” appearance.[74]

Struvite stones edit

About 10–15% of urinary calculi are composed of struvite (hexa-hydrated ammonium magnesium phosphate, NH4MgPO4·6H2O).[75] Struvite stones (also known as "infection stones," urease, or triple-phosphate stones) form most often in the presence of infection by urea-splitting bacteria. Using the enzyme urease, these organisms metabolize urea into ammonia and carbon dioxide. This alkalinizes the urine, resulting in favorable conditions for the formation of struvite stones. Proteus mirabilis, Proteus vulgaris, and Morganella morganii are the most common organisms isolated; less common organisms include Ureaplasma urealyticum and some species of Providencia, Klebsiella, Serratia, and Enterobacter. These infection stones are commonly observed in people who have factors that predispose them to urinary tract infections, such as those with spinal cord injury and other forms of neurogenic bladder, ileal conduit urinary diversion, vesicoureteral reflux, and obstructive uropathies. They are also commonly seen in people with underlying metabolic disorders, such as idiopathic hypercalciuria, hyperparathyroidism, and gout. Infection stones can grow rapidly, forming large calyceal staghorn (antler-shaped) calculi requiring invasive surgery such as percutaneous nephrolithotomy for definitive treatment.[75]

Struvite stones (triple-phosphate/magnesium ammonium phosphate) have a 'coffin lid' morphology by microscopy.[74]

Uric acid stones edit

About 5–10% of all stones are formed from uric acid.[21] People with certain metabolic abnormalities, including obesity,[30] may produce uric acid stones. They also may form in association with conditions that cause hyperuricosuria (an excessive amount of uric acid in the urine) with or without hyperuricemia (an excessive amount of uric acid in the serum). They may also form in association with disorders of acid/base metabolism where the urine is excessively acidic (low pH), resulting in precipitation of uric acid crystals. A diagnosis of uric acid urolithiasis is supported by the presence of a radiolucent stone in the face of persistent urine acidity, in conjunction with the finding of uric acid crystals in fresh urine samples.[76]

As noted above (section on calcium oxalate stones), people with inflammatory bowel disease (Crohn's disease, ulcerative colitis) tend to have hyperoxaluria and form oxalate stones. They also have a tendency to form urate stones. Urate stones are especially common after colon resection.

Uric acid stones appear as pleomorphic crystals, usually diamond-shaped. They may also look like squares or rods which are polarizable.[74]

Other types edit

People with certain rare inborn errors of metabolism have a propensity to accumulate crystal-forming substances in their urine. For example, those with cystinuria, cystinosis, and Fanconi syndrome may form stones composed of cystine. Cystine stone formation can be treated with urine alkalinization and dietary protein restriction. People affected by xanthinuria often produce stones composed of xanthine. People affected by adenine phosphoribosyltransferase deficiency may produce 2,8-dihydroxyadenine stones,[77] alkaptonurics produce homogentisic acid stones, and iminoglycinurics produce stones of glycine, proline, and hydroxyproline.[78][79] Urolithiasis has also been noted to occur in the setting of therapeutic drug use, with crystals of drug forming within the renal tract in some people currently being treated with agents such as indinavir,[80] sulfadiazine,[81] and triamterene.[82]

Location edit

 
Illustration of kidney stones

Urolithiasis refers to stones originating anywhere in the urinary system, including the kidneys and bladder.[16] Nephrolithiasis refers to the presence of such stones in the kidneys. Calyceal calculi are aggregations in either the minor or major calyx, parts of the kidney that pass urine into the ureter (the tube connecting the kidneys to the urinary bladder). The condition is called ureterolithiasis when a calculus is located in the ureter. Stones may also form or pass into the bladder, a condition referred to as bladder stones.[83]

Size edit

 
Radiograph showing a large staghorn calculus involving the major calyces and renal pelvis in a person with severe scoliosis

Stones less than 5 mm (0.2 in) in diameter pass spontaneously in up to 98% of cases, while those measuring 5 to 10 mm (0.2 to 0.4 in) in diameter pass spontaneously in less than 53% of cases.[84]

Stones that are large enough to fill out the renal calyces are called staghorn stones and are composed of struvite in a vast majority of cases, which forms only in the presence of urease-forming bacteria. Other forms that can possibly grow to become staghorn stones are those composed of cystine, calcium oxalate monohydrate, and uric acid.[85]

Prevention edit

Preventative measures depend on the type of stones. In those with calcium stones, drinking plenty of fluids, thiazide diuretics and citrate are effective as is allopurinol in those with high uric acid levels in urine.[86][87]

Dietary measures edit

See also: Hypocitraturia

Specific therapy should be tailored to the type of stones involved. Diet can have an effect on the development of kidney stones. Preventive strategies include some combination of dietary modifications and medications with the goal of reducing the excretory load of calculogenic compounds on the kidneys.[32][88][89] Dietary recommendations to minimize the formation of kidney stones include:

  • increasing total fluid intake to achieve more than two liters per day of urine output;[90]
  • limiting cola, including sugar-sweetened soft drinks;[86][90][91] to less than one liter per week.[92]
  • limiting animal protein intake to no more than two meals daily (an association between animal protein and recurrence of kidney stones has been shown in men);[93]
  • increasing citrate, or alkali intake, including from lemon and lime juice.[94] Citric acid in its natural form, such as from citrus fruits, "prevents small stones from becoming 'problem stones' by coating them and preventing other material from attaching and building onto the stones."[95];
  • reducing sodium intake is associated with a reduction in urine calcium excretion.

Maintenance of dilute urine by means of vigorous fluid therapy is beneficial in all forms of kidney stones, so increasing urine volume is a key principle for the prevention of kidney stones. Fluid intake should be sufficient to maintain a urine output of at least 2 litres (68 US fl oz) per day.[87] A high fluid intake may reduce the likelihood of kidney stone recurrence or may increase the time between stone development without unwanted effects.

Calcium binds with available oxalate in the gastrointestinal tract, thereby preventing its absorption into the bloodstream. Reducing oxalate absorption decreases kidney stone risk in susceptible people.[96] Because of this, some doctors recommend increasing dairy intake so that its calcium content will serve as an oxalate binder. Taking calcium citrate tablets during or after meals containing high oxalate foods[97] may be useful if dietary calcium cannot be increased by other means as in those with lactose intolerance. The preferred calcium supplement for people at risk of stone formation is calcium citrate, as opposed to calcium carbonate, because it helps to increase urinary citrate excretion.[89]

Aside from vigorous oral hydration and eating more dietary calcium, other prevention strategies include avoidance of higher doses of supplemental vitamin C (since ascorbate is metabolized to oxalate) and restriction of oxalate-rich foods such as leaf vegetables, rhubarb, soy products and chocolate.[98] However, no randomized, controlled trial of oxalate restriction has been performed to test the hypothesis that oxalate restriction reduces stone formation.[97] Some evidence indicates magnesium intake decreases the risk of symptomatic kidney stones.[98]

Urine alkalinization edit

The mainstay for medical management of uric acid stones is alkalinization (increasing the pH) of the urine. Uric acid stones are among the few types amenable to dissolution therapy, referred to as chemolysis. Chemolysis is usually achieved through the use of oral medications, although in some cases, intravenous agents or even instillation of certain irrigating agents directly onto the stone can be performed, using antegrade nephrostomy or retrograde ureteral catheters.[42] Acetazolamide is a medication that alkalinizes the urine. In addition to acetazolamide or as an alternative, certain dietary supplements are available that produce a similar alkalinization of the urine. These include alkali citrate, sodium bicarbonate, potassium citrate, magnesium citrate, and bicitrate (a combination of citric acid monohydrate and sodium citrate dihydrate).[99] Aside from alkalinization of the urine, these supplements have the added advantage of increasing the urinary citrate level, which helps to reduce the aggregation of calcium oxalate stones.[42]

Increasing the urine pH to around 6.5 provides optimal conditions for dissolution of uric acid stones. Increasing the urine pH to a value higher than 7.0 may increase the risk of calcium phosphate stone formation, though this concept is controversial since citrate does inhibit calcium phosphate crystallization. Testing the urine periodically with nitrazine paper can help to ensure the urine pH remains in this optimal range. Using this approach, stone dissolution rate can be expected to be around 10 mm (0.4 in) of stone radius per month.[42]

Slaked lime edit

Calcium hydroxide decreases urinary calcium when combined with food rich in oxalic acid such as green leafy vegetables.[100]

Diuretics edit

One of the recognized medical therapies for prevention of stones is the thiazide and thiazide-like diuretics, such as chlorthalidone or indapamide. These drugs inhibit the formation of calcium-containing stones by reducing urinary calcium excretion.[14] Sodium restriction is necessary for clinical effect of thiazides, as sodium excess promotes calcium excretion. Thiazides work best for renal leak hypercalciuria (high urine calcium levels), a condition in which high urinary calcium levels are caused by a primary kidney defect. Thiazides are useful for treating absorptive hypercalciuria, a condition in which high urinary calcium is a result of excess absorption from the gastrointestinal tract.[52]

Allopurinol edit

For people with hyperuricosuria and calcium stones, allopurinol is one of the few treatments that have been shown to reduce kidney stone recurrences. Allopurinol interferes with the production of uric acid in the liver. The drug is also used in people with gout or hyperuricemia (high serum uric acid levels).[101] Dosage is adjusted to maintain a reduced urinary excretion of uric acid. Serum uric acid level at or below 6 mg/100 mL is often a therapeutic goal. Hyperuricemia is not necessary for the formation of uric acid stones; hyperuricosuria can occur in the presence of normal or even low serum uric acid. Some practitioners advocate adding allopurinol only in people in whom hyperuricosuria and hyperuricemia persist, despite the use of a urine-alkalinizing agent such as sodium bicarbonate or potassium citrate.[42]

Treatment edit

Stone size influences the rate of spontaneous stone passage. For example, up to 98% of small stones (less than 5 mm (0.2 in) in diameter) may pass spontaneously through urination within four weeks of the onset of symptoms,[7] but for larger stones (5 to 10 mm (0.2 to 0.4 in) in diameter), the rate of spontaneous passage decreases to less than 53%.[84] Initial stone location also influences the likelihood of spontaneous stone passage. Rates increase from 48% for stones located in the proximal ureter to 79% for stones located at the vesicoureteric junction, regardless of stone size.[84] Assuming no high-grade obstruction or associated infection is found in the urinary tract, and symptoms are relatively mild, various nonsurgical measures can be used to encourage the passage of a stone.[42] Repeat stone formers benefit from more intense management, including proper fluid intake and use of certain medications, as well as careful monitoring.[102]

Pain management edit

Management of pain often requires intravenous administration of NSAIDs or opioids.[14] NSAIDs appear somewhat better than opioids or paracetamol in those with normal kidney function.[103] Medications by mouth are often effective for less severe discomfort.[66] The use of antispasmodics does not have further benefit.[9]

Medical expulsive therapy edit

The use of medications to speed the spontaneous passage of stones in the ureter is referred to as medical expulsive therapy.[104][105] Several agents, including alpha adrenergic blockers (such as tamsulosin) and calcium channel blockers (such as nifedipine), may be effective.[104] Alpha-blockers likely result in more people passing their stones, and they may pass their stones in a shorter time.[105] People taking alpha-blockers may also use less pain medication and may not need to visit the hospital.[105] Alpha-blockers appear to be more effective for larger stones (over 5 mm in size) than smaller stones.[105] However, use of alpha-blockers may be associated with a slight increase in serious, unwanted effects from this medication.[105] A combination of tamsulosin and a corticosteroid may be better than tamsulosin alone.[104] These treatments also appear to be useful in addition to lithotripsy.[7]

Lithotripsy edit

 
A lithotriptor machine with a mobile fluoroscopic system ("C-arm") is seen in an operating room; other equipment is seen in the background including an anesthesia machine.

Extracorporeal shock wave lithotripsy (ESWL) is a noninvasive technique for the removal of kidney stones. Most ESWL is carried out when the stone is present near the renal pelvis. ESWL involves the use of a lithotriptor machine to deliver externally applied, focused, high-intensity pulses of ultrasonic energy to cause fragmentation of a stone over a period of around 30–60 minutes. Following its introduction in the United States in February 1984, ESWL was rapidly and widely accepted as a treatment alternative for renal and ureteral stones.[106] It is currently used in the treatment of uncomplicated stones located in the kidney and upper ureter, provided the aggregate stone burden (stone size and number) is less than 20 mm (0.8 in) and the anatomy of the involved kidney is normal.[107][108]

For a stone greater than 10 millimetres (0.39 in), ESWL may not help break the stone in one treatment; instead, two or three treatments may be needed. Some 80-85% of simple renal calculi can be effectively treated with ESWL.[7] A number of factors can influence its efficacy, including chemical composition of the stone, presence of anomalous renal anatomy and the specific location of the stone within the kidney, presence of hydronephrosis, body mass index, and distance of the stone from the surface of the skin.[106]

Common adverse effects of ESWL include acute trauma, such as bruising at the site of shock administration, and damage to blood vessels of the kidney.[109][110] In fact, the vast majority of people who are treated with a typical dose of shock waves using currently accepted treatment settings are likely to experience some degree of acute kidney injury.[106] ESWL-induced acute kidney injury is dose-dependent (increases with the total number of shock waves administered and with the power setting of the lithotriptor) and can be severe,[106] including internal bleeding and subcapsular hematomas. On rare occasions, such cases may require blood transfusion and even lead to acute kidney failure. Hematoma rates may be related to the type of lithotriptor used; hematoma rates of less than 1% and up to 13% have been reported for different lithotriptor machines.[110] Recent studies show reduced acute tissue injury when the treatment protocol includes a brief pause following the initiation of treatment, and both improved stone breakage and a reduction in injury when ESWL is carried out at slow shock wave rate.[106]

In addition to the aforementioned potential for acute kidney injury, animal studies suggest these acute injuries may progress to scar formation, resulting in loss of functional renal volume.[109][110] Recent prospective studies also indicate elderly people are at increased risk of developing new-onset hypertension following ESWL. In addition, a retrospective case-control study published by researchers from the Mayo Clinic in 2006 has found an increased risk of developing diabetes mellitus and hypertension in people who had undergone ESWL, compared with age and gender-matched people who had undergone nonsurgical treatment. Whether or not acute trauma progresses to long-term effects probably depends on multiple factors that include the shock wave dose (i.e., the number of shock waves delivered, rate of delivery, power setting, acoustic characteristics of the particular lithotriptor, and frequency of retreatment), as well as certain intrinsic predisposing pathophysiologic risk factors.[106]

To address these concerns, the American Urological Association established the Shock Wave Lithotripsy Task Force to provide an expert opinion on the safety and risk-benefit ratio of ESWL. The task force published a white paper outlining their conclusions in 2009. They concluded the risk-benefit ratio remains favorable for many people.[106] The advantages of ESWL include its noninvasive nature, the fact that it is technically easy to treat most upper urinary tract calculi, and that, at least acutely, it is a well-tolerated, low-morbidity treatment for the vast majority of people. However, they recommended slowing the shock wave firing rate from 120 pulses per minute to 60 pulses per minute to reduce the risk of renal injury and increase the degree of stone fragmentation.[106]

Alpha-blockers are sometimes prescribed after shock wave lithotripsy to help the pieces of the stone leave the person's body.[111] By relaxing muscles and helping to keep blood vessels open, alpha blockers may relax the ureter muscles to allow the kidney stone fragments to pass. When compared to usual care or placebo treatment, alpha blockers may lead to faster clearing of stones, a reduced need for extra treatment and fewer unwanted effects.[111] They may also clear kidney stones in more adults than the standard shock wave lithotripsy procedure. The unwanted effects associated with alpha blockers are hospital emergency visits and return to hospital for stone-related issues, but these effects were more common in adults who did not receive alpha-blockers as a part of their treatment.[111]

Surgery edit

 
Three-dimensional reconstructed CT scan image of a ureteral stent in the left kidney (indicated by yellow arrow), with a kidney stone in the inferior renal pelvis (highest red arrow) and one in the ureter beside the stent (lower red arrow)
 
A kidney stone at the tip of an ultrasonic stone disintegration apparatus

Most stones under 5 mm (0.2 in) pass spontaneously.[32][7] Prompt surgery may, nonetheless, be required in persons with only one working kidney, bilateral obstructing stones, a urinary tract infection and thus, it is presumed, an infected kidney, or intractable pain.[112] Beginning in the mid-1980s, less invasive treatments such as extracorporeal shock wave lithotripsy, ureteroscopy, and percutaneous nephrolithotomy began to replace open surgery as the modalities of choice for the surgical management of urolithiasis.[7] More recently, flexible ureteroscopy has been adapted to facilitate retrograde nephrostomy creation for percutaneous nephrolithotomy. This approach is still under investigation, though early results are favorable.[113] Percutaneous nephrolithotomy or, rarely, anatrophic nephrolithotomy, is the treatment of choice for large or complicated stones (such as calyceal staghorn calculi) or stones that cannot be extracted using less invasive procedures.[56][7]

Ureteroscopic surgery edit

Ureteroscopy has become increasingly popular as flexible and rigid fiberoptic ureteroscopes have become smaller. One ureteroscopic technique involves the placement of a ureteral stent (a small tube extending from the bladder, up the ureter and into the kidney) to provide immediate relief of an obstructed kidney. Stent placement can be useful for saving a kidney at risk for postrenal acute kidney failure due to the increased hydrostatic pressure, swelling and infection (pyelonephritis and pyonephrosis) caused by an obstructing stone. Ureteral stents vary in length from 24 to 30 cm (9.4 to 11.8 in) and most have a shape commonly referred to as a "double-J" or "double pigtail", because of the curl at both ends. They are designed to allow urine to flow past an obstruction in the ureter. They may be retained in the ureter for days to weeks as infections resolve and as stones are dissolved or fragmented by ESWL or by some other treatment. The stents dilate the ureters, which can facilitate instrumentation, and they also provide a clear landmark to aid in the visualization of the ureters and any associated stones on radiographic examinations. The presence of indwelling ureteral stents may cause minimal to moderate discomfort, frequency or urgency incontinence, and infection, which in general resolves on removal. Most ureteral stents can be removed cystoscopically during an office visit under topical anesthesia after resolution of urolithiasis.[114] Research is currently uncertain if placing a temporary stent during ureteroscopy leads to different outcomes than not placing a stent in terms of number of hospital visits for post operative problems, short or long term pain, need for narcotic pain medication, risk of UTI, need for a repeat procedure or narrowing of the ureter from scarring.[115]

More definitive ureteroscopic techniques for stone extraction (rather than simply bypassing the obstruction) include basket extraction and ultrasound ureterolithotripsy. Laser lithotripsy is another technique, which involves the use of a holmium:yttrium aluminium garnet (Ho:YAG) laser to fragment stones in the bladder, ureters, and kidneys.[116]

Ureteroscopic techniques are generally more effective than ESWL for treating stones located in the lower ureter, with success rates of 93–100% using Ho:YAG laser lithotripsy.[84] Although ESWL has been traditionally preferred by many practitioners for treating stones located in the upper ureter, more recent experience suggests ureteroscopic techniques offer distinct advantages in the treatment of upper ureteral stones. Specifically, the overall success rate is higher, fewer repeat interventions and postoperative visits are needed, and treatment costs are lower after ureteroscopic treatment when compared with ESWL. These advantages are especially apparent with stones greater than 10 mm (0.4 in) in diameter. However, because ureteroscopy of the upper ureter is much more challenging than ESWL, many urologists still prefer to use ESWL as a first-line treatment for stones of less than 10 mm, and ureteroscopy for those greater than 10 mm in diameter.[84] Ureteroscopy is the preferred treatment in pregnant and morbidly obese people, as well as those with bleeding disorders.[7]

Epidemiology edit

Country Earliest prevalence (years)[117] Latest prevalence (years)[117]
United States 2.6% (1964–1972) 5.2% (1988–1994)
Italy 1.2% (1983) 1.7% (1993–1994)
Scotland 3.8% (1977) 3.5% (1987)
Spain 0.1% (1977) 10.0% (1991)
Turkey n/a 14.8% (1989)
Country New cases per 100,000 (year)[117] Trend
United States 116 (2000) decreasing
Germany 720 (2000) increasing
Japan 114.3 (2005) increasing
Spain 270 (1984) decreasing
Sweden 200 (1969) increasing
 
Urolithiasis deaths per million persons in 2012
  0–0
  1–1
  2–2
  3–3
  4–20

Kidney stones affect all geographical, cultural, and racial groups. The lifetime risk is about 10-15% in the developed world, but can be as high as 20-25% in the Middle East. The increased risk of dehydration in hot climates, coupled with a diet 50% lower in calcium and 250% higher in oxalates compared to Western diets, accounts for the higher net risk in the Middle East.[118] In the Middle East, uric acid stones are more common than calcium-containing stones.[25] The number of deaths due to kidney stones is estimated at 19,000 per year being fairly consistent between 1990 and 2010.[119]

In North America and Europe, the annual number of new cases per year of kidney stones is roughly 0.5%. In the United States, the frequency in the population of urolithiasis has increased from 3.2% to 5.2% from the mid-1970s to the mid-1990s.[21] In the United States, about 9% of the population has had a kidney stone.[2]

The total cost for treating urolithiasis was US$2 billion in 2003.[58] About 65–80% of those with kidney stones are men; most stones in women are due to either metabolic defects (such as cystinuria) or infections in the case of struvite stones.[75][120][19] Urinary tract calculi disorders are more common in men than in women. Men most commonly experience their first episode between 30 and 40 years of age, whereas for women, the age at first presentation is somewhat later.[75] The age of onset shows a bimodal distribution in women, with episodes peaking at 35 and 55 years.[58] Recurrence rates are estimated at 50% over a 10-year and 75% over 20-year period,[21] with some people experiencing ten or more episodes over the course of a lifetime.[75]

A 2010 review concluded that rates of disease are increasing.[117]

History edit

See also: List of kidney stone formers

The existence of kidney stones was first recorded thousands of years ago, with various explanations given; Joseph Glanville's Saducismus Triumphatus, for example, gives a detailed description of Abraham Mechelburg's voiding of small stones through his penis' virga, attributing the issue to witchcraft.[121]

In 1901, a stone discovered in the pelvis of an ancient Egyptian mummy was dated to 4,800 BC.

Medical texts from ancient Mesopotamia, India, China, Persia, Greece, and Rome all mentioned calculous disease. Part of the Hippocratic Oath suggests there were practicing surgeons in ancient Greece to whom physicians were to defer for lithotomies, or the surgical removal of stones. The Roman medical treatise De Medicina by Aulus Cornelius Celsus contained a description of lithotomy,[122] and this work served as the basis for this procedure until the 18th century.[123]

Examples of people who had kidney stone disease include Napoleon I, Epicurus, Napoleon III, Peter the Great, Louis XIV, George IV, Oliver Cromwell, Lyndon B. Johnson, Benjamin Franklin, Michel de Montaigne, Francis Bacon, Isaac Newton, Samuel Pepys, William Harvey, Herman Boerhaave, and Antonio Scarpa.[124]

New techniques in lithotomy began to emerge starting in 1520, but the operation remained risky. After Henry Jacob Bigelow popularized the technique of litholapaxy in 1878,[125] the mortality rate dropped from about 24% to 2.4%. However, other treatment techniques continued to produce a high level of mortality, especially among inexperienced urologists.[123][124] In 1980, Dornier MedTech introduced extracorporeal shock wave lithotripsy for breaking up stones via acoustical pulses, and this technique has since come into widespread use.[106]

Etymology edit

The term renal calculus is from the Latin rēnēs, meaning "kidneys", and calculus, meaning "pebble". Lithiasis (stone formation) in the kidneys is called nephrolithiasis (/ˌnɛfroʊlɪˈθaɪəsɪs/), from nephro-, meaning kidney, + -lith, meaning stone, and -iasis, meaning disorder. A distinction between nephrolithiasis and urolithiasis can be made because not all urinary stones (uroliths) form in the kidney; they can also form in the bladder. But the distinction is often clinically irrelevant (with similar disease process and treatment either way) and the words are thus often used loosely as synonyms.

Children edit

Although kidney stones do not often occur in children, the incidence is increasing.[126] These stones are in the kidney in two thirds of reported cases, and in the ureter in the remaining cases. Older children are at greater risk independent of whether or not they are male or female.[127]

As with adults, most pediatric kidney stones are predominantly composed of calcium oxalate; struvite and calcium phosphate stones are less common. Calcium oxalate stones in children are associated with high amounts of calcium, oxalate, and magnesium in acidic urine.[128]

Treatment of kidney stones in children is similar to treatments for adults, including shock wave lithotripsy, medication, and treatment using scope through the bladder, kidney or skin.[129] Of these treatments, research is uncertain if shock waves are more effective than medication or a scope through the bladder, but it is likely less successful than a scope through skin into the kidney.[129] When going in with a scope through the kidney, a regular and a mini-sized scope likely have similar success rates of stone removal. Alpha-blockers, a type of medication, may increase the successful removal of kidney stones when compared with a placebo and without ibuprofen.[129]

Research edit

Metabolic syndrome and its associated diseases of obesity and diabetes as general risk factors for kidney stone disease are under research to determine if urinary excretion of calcium, oxalate and urate are higher than in people with normal weight or underweight, and if diet and physical activity have roles.[130][131] Dietary, fluid intake, and lifestyle factors remain major topics for research on prevention of kidney stones, as of 2017.[132]

Gut microbiota edit

The gut microbiota has been explored as a contributing factor for stone disease, indicating that some bacteria may be different in people forming kidney stones.[133] One bacterium, Oxalobacter formigenes, is potentially beneficial for mitigating calcium oxalate stones because of its ability to metabolize oxalate as its sole carbon source,[134] but 2018 research suggests that it is instead part of a network of oxalate degrading bacteria.[135] Additionally, one study found that oral antibiotic use, which alters the gut microbiota,[136] can increase the odds of a person developing a kidney stone.[137]

In animals edit

Among ruminants, uroliths more commonly cause problems in males than in females; the sigmoid flexure of the ruminant male urinary tract is more likely to obstruct passage. Early-castrated males are at greater risk, because of lesser urethral diameter.[138]

Low Ca:P intake ratio is conducive to phosphatic (e.g. struvite) urolith formation.[138] Incidence among wether lambs can be minimized by maintaining a dietary Ca:P intake ratio of 2:1.[138][139]

Alkaline (higher) pH favors formation of carbonate and phosphate calculi. For domestic ruminants, dietary cation: anion balance is sometimes adjusted to assure a slightly acidic urine pH, for prevention of calculus formation.[138]

Differing generalizations regarding effects of pH on formation of silicate uroliths may be found.[138][140] In this connection, it may be noted that under some circumstances, calcium carbonate accompanies silica in siliceous uroliths.[141]

Pelleted feeds may be conducive to formation of phosphate uroliths, because of increased urinary phosphorus excretion. This is attributable to lower saliva production where pelleted rations containing finely ground constituents are fed. With less blood phosphate partitioned into saliva, more tends to be excreted in urine.[142] (Most saliva phosphate is fecally excreted.[143])

Oxalate uroliths can occur in ruminants, although such problems from oxalate ingestion may be relatively uncommon. Ruminant urolithiasis associated with oxalate ingestion has been reported.[144] However, no renal tubular damage or visible deposition of calcium oxalate crystals in kidneys was found in yearling wether sheep fed diets containing soluble oxalate at 6.5 percent of dietary dry matter for about 100 days.[145]

Conditions limiting water intake can result in stone formation.[146]

Various surgical interventions, e.g. amputation of the urethral process at its base near the glans penis in male ruminants, perineal urethrostomy, or tube cystostomy may be considered for relief of obstructive urolithiasis.[146]

See also edit

References edit

  1. ^ a b Schulsinger DA (2014). Kidney Stone Disease: Say NO to Stones!. Springer. p. 27. ISBN 978-3-319-12105-5. from the original on 8 September 2017.
  2. ^ a b c d e f g h i j k l m n o p q r s . February 2013. Archived from the original on 11 May 2015. Retrieved 22 May 2015.
  3. ^ Knoll T, Pearle MS (2012). Clinical Management of Urolithiasis. Springer Science & Business Media. p. 21. ISBN 978-3-642-28732-9. from the original on 8 September 2017.
  4. ^ a b c d Qaseem A, Dallas P, Forciea MA, Starkey M, Denberg TD (November 2014). "Dietary and pharmacologic management to prevent recurrent nephrolithiasis in adults: a clinical practice guideline from the American College of Physicians". Annals of Internal Medicine. 161 (9): 659–67. doi:10.7326/M13-2908. PMID 25364887.
  5. ^ a b Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, Carter A, Casey DC, Charlson FJ, Chen AZ, Coggeshall M, Cornaby L, Dandona L, Dicker DJ, Dilegge T, Erskine HE, Ferrari AJ, Fitzmaurice C, Fleming T, Forouzanfar MH, Fullman N, Gething PW, Goldberg EM, Graetz N, Haagsma JA, Hay SI, Johnson CO, Kassebaum NJ, Kawashima T, Kemmer L, et al. (GBD 2015 Disease and Injury Incidence and Prevalence Collaborators) (October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282.
  6. ^ a b Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, Casey DC, Charlson FJ, Chen AZ, Coates MM, Coggeshall M, Dandona L, Dicker DJ, Erskine HE, Ferrari AJ, Fitzmaurice C, Foreman K, Forouzanfar MH, Fraser MS, Fullman N, Gething PW, Goldberg EM, Graetz N, Haagsma JA, Hay SI, Huynh C, Johnson CO, Kassebaum NJ, Kinfu Y, Kulikoff XR, et al. (GBD 2015 Disease and Injury Incidence and Prevalence Collaborators) (October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1. PMC 5388903. PMID 27733281.
  7. ^ a b c d e f g h i j Miller NL, Lingeman JE (March 2007). "Management of kidney stones". BMJ. 334 (7591): 468–72. doi:10.1136/bmj.39113.480185.80. PMC 1808123. PMID 17332586.
  8. ^ a b c d Morgan MS, Pearle MS (March 2016). "Medical management of renal stones". BMJ. 352: i52. doi:10.1136/bmj.i52. PMID 26977089. S2CID 28313474.
  9. ^ a b Afshar K, Jafari S, Marks AJ, Eftekhari A, MacNeily AE (June 2015). "Nonsteroidal anti-inflammatory drugs (NSAIDs) and non-opioids for acute renal colic". The Cochrane Database of Systematic Reviews. 2015 (6): CD006027. doi:10.1002/14651858.CD006027.pub2. PMC 10981792. PMID 26120804.
  10. ^ Wang RC, Smith-Bindman R, Whitaker E, Neilson J, Allen IE, Stoller ML, Fahimi J (March 2017). "Effect of Tamsulosin on Stone Passage for Ureteral Stones: A Systematic Review and Meta-analysis". Annals of Emergency Medicine. 69 (3): 353–361.e3. doi:10.1016/j.annemergmed.2016.06.044. PMID 27616037.
  11. ^ a b Abufaraj M, Xu T, Cao C, Waldhoer T, Seitz C, D'andrea D, Siyam A, Tarawneh R, Fajkovic H, Schernhammer E, Yang L, Shariat SF (November 2021). "Prevalence and Trends in Kidney Stone Among Adults in the USA: Analyses of National Health and Nutrition Examination Survey 2007-2018 Data". European Urology Focus. 7 (6): 1468–1475. doi:10.1016/j.euf.2020.08.011. PMID 32900675. S2CID 221572651.
  12. ^ Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC (May 2003). "Time trends in reported prevalence of kidney stones in the United States: 1976–199411.See Editorial by Goldfarb, p. 1951". Kidney International. 63 (5): 1817–1823. doi:10.1046/j.1523-1755.2003.00917.x. PMID 12675858.
  13. ^ Stamatelou K, Goldfarb DS (January 2023). "Epidemiology of Kidney Stones". Healthcare. 11 (3): 424. doi:10.3390/healthcare11030424. ISSN 2227-9032. PMC 9914194. PMID 36766999.  This article incorporates text from this source, which is available under the CC BY 4.0 license.
  14. ^ a b c d e f g Preminger GM (2007). "Chapter 148: Stones in the Urinary Tract". In Cutler RE (ed.). The Merck Manual of Medical Information Home Edition (3rd ed.). Whitehouse Station, New Jersey: Merck Sharp and Dohme Corporation. from the original on 8 December 2014. Retrieved 7 August 2011.
  15. ^ Nephrolithiasis~Overview at eMedicine § Background.
  16. ^ a b c Pearle MS, Calhoun EA, Curhan GC (2007). "Ch. 8: Urolithiasis" (PDF). In Litwin MS, Saigal CS (eds.). Urologic Diseases in America (NIH Publication No. 07–5512). Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, United States Public Health Service, United States Department of Health and Human Services. pp. 283–319. (PDF) from the original on 18 October 2011.
  17. ^ a b Cavendish M (2008). "Kidney disorders". Diseases and Disorders. Vol. 2 (1st ed.). Tarrytown, New York: Marshall Cavendish Corporation. pp. 490–3. ISBN 978-0-7614-7772-3. from the original on 14 April 2021. Retrieved 6 November 2020.
  18. ^ a b Curhan GC, Willett WC, Rimm EB, Spiegelman D, Stampfer MJ (February 1996). "Prospective study of beverage use and the risk of kidney stones". American Journal of Epidemiology. 143 (3): 240–7. doi:10.1093/oxfordjournals.aje.a008734. PMID 8561157.
  19. ^ a b c d Lewis SM (2017). Medical-surgical nursing : assessment and management of clinical problems. Elsevier. ISBN 978-0-323-32852-4. OCLC 944472408.
  20. ^ Knight J, Assimos DG, Easter L, Holmes RP (November 2010). "Metabolism of fructose to oxalate and glycolate". Hormone and Metabolic Research. 42 (12): 868–73. doi:10.1055/s-0030-1265145. PMC 3139422. PMID 20842614.
  21. ^ a b c d Moe OW (January 2006). "Kidney stones: pathophysiology and medical management" (PDF). Lancet. 367 (9507): 333–44. doi:10.1016/S0140-6736(06)68071-9. PMID 16443041. S2CID 26581831. (PDF) from the original on 15 August 2011.
  22. ^ Thakker RV (March 2000). "Pathogenesis of Dent's disease and related syndromes of X-linked nephrolithiasis" (PDF). Kidney International. 57 (3): 787–93. doi:10.1046/j.1523-1755.2000.00916.x. PMID 10720930. (PDF) from the original on 5 November 2012.
  23. ^ a b National Endocrine and Metabolic Diseases Information Service (2006). . Information about Endocrine and Metabolic Diseases: A-Z list of Topics and Titles. Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Public Health Service, US Department of Health and Human Services. Archived from the original on 24 May 2011. Retrieved 27 July 2011.
  24. ^ a b Hoppe B, Langman CB (October 2003). "A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria". Pediatric Nephrology. 18 (10): 986–91. doi:10.1007/s00467-003-1234-x. PMID 12920626. S2CID 23503869.
  25. ^ a b c d e Reilly RF, Ch. 13: "Nephrolithiasis". In Reilly & Perazella 2005, pp. 192–207.
  26. ^ National Kidney and Urologic Diseases Information Clearinghouse (2008). . Kidney & Urologic Diseases: A-Z list of Topics and Titles. Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Public Health Service, US Department of Health and Human Services. Archived from the original on 7 August 2011. Retrieved 27 July 2011.
  27. ^ National Digestive Diseases Information Clearinghouse (2006). . Digestive Diseases: A-Z List of Topics and Titles. Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, United States Public Health Service, United States Department of Health and Human Services. Archived from the original on 9 June 2014. Retrieved 27 July 2011.
  28. ^ Farmer RG, Mir-Madjlessi SH, Kiser WS (1974). "Urinary excretion of oxalate, calcium, magnesium, and uric acid in inflammatory bowel disease". Cleveland Clinic Quarterly. 41 (3): 109–17. doi:10.3949/ccjm.41.3.109. PMID 4416806. from the original on 20 March 2020. Retrieved 1 November 2013.
  29. ^ a b c "Tolerable upper intake levels: Calcium and vitamin D". In Committee to Review Dietary Reference Intakes for Vitamin D and Calcium 2011, pp. 403–56.
  30. ^ a b c d e f g h Johri N, Cooper B, Robertson W, Choong S, Rickards D, Unwin R (2010). "An update and practical guide to renal stone management". Nephron Clinical Practice. 116 (3): c159-71. doi:10.1159/000317196. PMID 20606476. from the original on 31 January 2021. Retrieved 18 May 2019.
  31. ^ "Summary". In Committee to Review Dietary Reference Intakes for Vitamin D and Calcium 2011, pp. 1–14.
  32. ^ a b c Parmar MS (June 2004). "Kidney stones". BMJ. 328 (7453): 1420–4. doi:10.1136/bmj.328.7453.1420. PMC 421787. PMID 15191979.
  33. ^ Liebman M, Al-Wahsh IA (May 2011). "Probiotics and other key determinants of dietary oxalate absorption" (PDF). Advances in Nutrition. 2 (3): 254–60. doi:10.3945/an.111.000414. PMC 3090165. PMID 22332057. (PDF) from the original on 16 January 2016.
  34. ^ Committee on Fluoride in Drinking Water of the National Academy of Sciences (2006). "Chapter 9: Effects on the Renal System". Fluoride in Drinking Water: A Scientific Review of EPA's Standards. Washington, DC: The National Academies Press. pp. 236–48. ISBN 978-0-309-65799-0. from the original on 30 July 2011.
  35. ^ Ferraro PM, Mandel EI, Curhan GC, Gambaro G, Taylor EN (October 2016). "Dietary Protein and Potassium, Diet-Dependent Net Acid Load, and Risk of Incident Kidney Stones". Clinical Journal of the American Society of Nephrology. 11 (10): 1834–1844. doi:10.2215/CJN.01520216. PMC 5053786. PMID 27445166.
  36. ^ a b Riley JM, Kim H, Averch TD, Kim HJ (December 2013). "Effect of magnesium on calcium and oxalate ion binding". Journal of Endourology. 27 (12): 1487–92. doi:10.1089/end.2013.0173. PMC 3883082. PMID 24127630.
  37. ^ a b Negri AL, Spivacow FR, Del Valle EE (2013). "[Diet in the treatment of renal lithiasis. Pathophysiological basis]". Medicina. 73 (3): 267–71. PMID 23732207.
  38. ^ Goodwin JS, Tangum MR (November 1998). "Battling quackery: attitudes about micronutrient supplements in American academic medicine". Archives of Internal Medicine. 158 (20): 2187–91. doi:10.1001/archinte.158.20.2187. PMID 9818798.
  39. ^ Traxer O, Pearle MS, Gattegno B, Thibault P (December 2003). "[Vitamin C and stone risk. Review of the literature]". Progres en Urologie. 13 (6): 1290–4. PMID 15000301.
  40. ^ Ferraro PM, Curhan GC, Gambaro G, Taylor EN (March 2016). "Total, Dietary, and Supplemental Vitamin C Intake and Risk of Incident Kidney Stones". American Journal of Kidney Diseases. 67 (3): 400–7. doi:10.1053/j.ajkd.2015.09.005. PMC 4769668. PMID 26463139.
  41. ^ Perazella MA, Ch. 14: "Urinalysis". In Reilly & Perazella 2005, pp. 209–26.
  42. ^ a b c d e f Knudsen BE, Beiko DT, Denstedt JD, Ch. 16: "Uric Acid Urolithiasis". In Stoller & Meng 2007, pp. 299–308.
  43. ^ Nephrolithiasis~Overview at eMedicine § Pathophysiology.
  44. ^ Robertson WG, Peacock M, Nordin BE (July 1969). "Calcium crystalluria in recurrent renal-stone formers". Lancet. 2 (7610): 21–24. doi:10.1016/S0140-6736(69)92598-7. PMID 4182793.
  45. ^ Elliot JS, Rabinowitz IN (March 1980). "Calcium oxalate crystalluria: crystal size in urine". The Journal of Urology. 123 (3): 324–327. doi:10.1016/S0022-5347(17)55918-2. PMID 7359628.
  46. ^ Randall A (June 1937). "The Origin and Growth of Renal Calculi". Annals of Surgery. 105 (6): 1009–1027. doi:10.1097/00000658-193706000-00014. PMC 1390483. PMID 17856988.
  47. ^ Ratkalkar VN, Kleinman JG (December 2011). "Mechanisms of Stone Formation". Clinical Reviews in Bone and Mineral Metabolism. 9 (3–4): 187–197. doi:10.1007/s12018-011-9104-8. PMC 3252394. PMID 22229020.
  48. ^ Khan SR (September 2014). "Reactive oxygen species, inflammation and calcium oxalate nephrolithiasis". Translational Andrology and Urology. 3 (3): 256–276. doi:10.3978/j.issn.2223-4683.2014.06.04. PMC 4220551. PMID 25383321.
  49. ^ Jones BD, Mobley HL (August 1988). "Proteus mirabilis urease: genetic organization, regulation, and expression of structural genes". Journal of Bacteriology. 170 (8): 3342–3349. doi:10.1128/jb.170.8.3342-3349.1988. PMC 211300. PMID 2841283.
  50. ^ Chmiel JA, Stuivenberg GA, Alathel A, Gorla J, Grohe B, Razvi H, Burton JP, Bjazevic J (December 2021). "High-Throughput in vitro Gel-Based Plate Assay to Screen for Calcium Oxalate Stone Inhibitors". Urologia Internationalis. 106 (6): 616–622. doi:10.1159/000519842. PMID 34883484. S2CID 245012979.
  51. ^ Kanlaya R, Naruepantawart O, Thongboonkerd V (5 November 2019). "Flagellum Is Responsible for Promoting Effects of Viable Escherichia coli on Calcium Oxalate Crystallization, Crystal Growth, and Crystal Aggregation". Frontiers in Microbiology. 10: 2507. doi:10.3389/fmicb.2019.02507. PMC 6848068. PMID 31749785.
  52. ^ a b c Coe FL, Evan A, Worcester E (October 2005). "Kidney stone disease". The Journal of Clinical Investigation. 115 (10): 2598–608. doi:10.1172/JCI26662. PMC 1236703. PMID 16200192.
  53. ^ del Valle EE, Spivacow FR, Negri AL (2013). "[Citrate and renal stones]". Medicina. 73 (4): 363–8. PMID 23924538.
  54. ^ "Educate Your Patients about Kidney Stones" (PDF). kidney.org. (PDF) from the original on 26 October 2020.
  55. ^ Caudarella R, Vescini F (September 2009). "Urinary citrate and renal stone disease: the preventive role of alkali citrate treatment". Archivio Italiano di Urologia, Andrologia. 81 (3): 182–7. PMID 19911682.
  56. ^ a b c d e Anoia EJ, Paik ML, Resnick MI (2009). "Ch. 7: Anatrophic Nephrolithomy". In Graham SD, Keane TE (eds.). Glenn's Urologic Surgery (7th ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 45–50. ISBN 978-0-7817-9141-0. from the original on 14 April 2021. Retrieved 6 November 2020.
  57. ^ Weaver SH, Jenkins P (2002). "Ch. 14: Renal and Urological Care". Illustrated Manual of Nursing Practice (3rd ed.). Lippincott Williams & Wilkins. ISBN 978-1-58255-082-4.
  58. ^ a b c d e f Pietrow PK, Karellas ME (July 2006). "Medical management of common urinary calculi" (PDF). American Family Physician. 74 (1): 86–94. PMID 16848382. (PDF) from the original on 23 November 2011.
  59. ^ Brisbane W, Bailey MR, Sorensen MD (November 2016). "An overview of kidney stone imaging techniques". Nature Reviews. Urology. 13 (11): 654–662. doi:10.1038/nrurol.2016.154. ISSN 1759-4812. PMC 5443345. PMID 27578040.
  60. ^ a b c Smith RC, Varanelli M (July 2000). "Diagnosis and management of acute ureterolithiasis: CT is truth". AJR. American Journal of Roentgenology. 175 (1): 3–6. doi:10.2214/ajr.175.1.1750003. PMID 10882237. S2CID 73387308.
  61. ^ Bushinsky D, Coe FL, Moe OW (2007). . In Brenner BM (ed.). Brenner and Rector's The Kidney. Vol. 1 (8th ed.). Philadelphia: WB Saunders. pp. 1299–349. ISBN 978-1-4160-3105-5. Archived from the original on 8 October 2011.
  62. ^ Smith RC, Levine J, Rosenfeld AT (September 1999). "Helical CT of urinary tract stones. Epidemiology, origin, pathophysiology, diagnosis, and management". Radiologic Clinics of North America. 37 (5): 911–52, v. doi:10.1016/S0033-8389(05)70138-X. PMID 10494278.
  63. ^ American College of Emergency Physicians (27 October 2014). "Ten Things Physicians and Patients Should Question". Choosing Wisely. from the original on 7 March 2014. Retrieved 14 January 2015.
  64. ^ . www.choosingwisely.org. Archived from the original on 23 February 2017. Retrieved 28 May 2017.
  65. ^ a b c Fang LS (2009). "Chapter 135: Approach to the Paient with Nephrolithiasis". In Goroll AH, Mulley AG (eds.). Primary care medicine: office evaluation and management of the adult patient (6th ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 962–7. ISBN 978-0-7817-7513-7. from the original on 21 March 2021. Retrieved 6 November 2020.
  66. ^ a b Semins MJ, Matlaga BR (September 2013). "Management of urolithiasis in pregnancy". International Journal of Women's Health. 5: 599–604. doi:10.2147/ijwh.s51416. PMC 3792830. PMID 24109196.
  67. ^ Smith-Bindman R, Aubin C, Bailitz J, Bengiamin RN, Camargo CA, Corbo J, Dean AJ, Goldstein RB, Griffey RT, Jay GD, Kang TL, Kriesel DR, Ma OJ, Mallin M, Manson W, Melnikow J, Miglioretti DL, Miller SK, Mills LD, Miner JR, Moghadassi M, Noble VE, Press GM, Stoller ML, Valencia VE, Wang J, Wang RC, Cummings SR (September 2014). "Ultrasonography versus computed tomography for suspected nephrolithiasis" (PDF). The New England Journal of Medicine. 371 (12): 1100–10. doi:10.1056/NEJMoa1404446. PMID 25229916. S2CID 4511678. (PDF) from the original on 14 March 2020. Retrieved 25 September 2019.
  68. ^ National Kidney and Urologic Diseases Information Clearinghouse (2007). . Kidney & Urologic Diseases: A-Z list of Topics and Titles. Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Public Health Service, US Department of Health and Human Services. Archived from the original on 26 July 2011. Retrieved 27 July 2011.
  69. ^ a b Frassetto L, Kohlstadt I (2011). "Treatment and prevention of kidney stones: an update". Am Fam Physician. 84 (11): 1234–42. PMID 22150656.
    Including cystine stone incidence of 1%
  70. ^ Becker KL (2001). Principles and practice of endocrinology and metabolism (3 ed.). Philadelphia, Pa. [u.a.]: Lippincott, Williams & Wilkins. p. 684. ISBN 978-0-7817-1750-2. from the original on 8 September 2017.
  71. ^ "Cystine stones". UpToDate. from the original on 26 February 2014. Retrieved 20 February 2014.
  72. ^ Bailey & Love's/25th/1296
  73. ^ National Endocrine and Metabolic Diseases Information Service (2008). . Kidney & Urologic Diseases: A-Z list of Topics and Titles. Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Public Health Service, US Department of Health and Human Services. Archived from the original on 28 July 2011. Retrieved 27 July 2011.
  74. ^ a b c d De Mais D (2009). ASCP Quick Compendium of Clinical Pathology (2nd ed.). Chicago: ASCP Press.
  75. ^ a b c d e Weiss M, Liapis H, Tomaszewski JE, Arend LJ (2007). "Chapter 22: Pyelonephritis and Other Infections, Reflux Nephropathy, Hydronephrosis, and Nephrolithiasis". In Jennette JC, Olson JL, Schwartz MM, Silva FG (eds.). Heptinstall's Pathology of the Kidney. Vol. 2 (6th ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 991–1082. ISBN 978-0-7817-4750-9. from the original on 20 March 2021. Retrieved 6 November 2020.
  76. ^ Halabe A, Sperling O (1994). "Uric acid nephrolithiasis". Mineral and Electrolyte Metabolism. 20 (6): 424–31. PMID 7783706.
  77. ^ Kamatani N (December 1996). "[Adenine phosphoribosyltransferase(APRT) deficiency]". Nihon Rinsho. Japanese Journal of Clinical Medicine (in Japanese). 54 (12): 3321–7. PMID 8976113.
  78. ^ Rosenberg LE, Durant JL, Elsas LJ (June 1968). "Familial iminoglycinuria. An inborn error of renal tubular transport". The New England Journal of Medicine. 278 (26): 1407–13. doi:10.1056/NEJM196806272782601. PMID 5652624.
  79. ^ Coşkun T, Ozalp I, Tokatli A (1993). "Iminoglycinuria: a benign type of inherited aminoaciduria". The Turkish Journal of Pediatrics. 35 (2): 121–5. PMID 7504361.
  80. ^ "Patient Information about Crixivan for HIV (Human Immunodeficiency Virus) Infection" (PDF). Crixivan® (indinavir sulfate) Capsules. Whitehouse Station, New Jersey: Merck Sharp & Dohme Corporation. 2010. (PDF) from the original on 15 August 2011. Retrieved 27 July 2011.
  81. ^ Schlossberg D, Samuel R (2011). "Sulfadiazine". Antibiotic Manual: A Guide to Commonly Used Antimicrobials (1st ed.). Shelton, Connecticut: People's Medical Publishing House. pp. 411–12. ISBN 978-1-60795-084-4. from the original on 20 March 2021. Retrieved 25 August 2020.
  82. ^ Carr MC, Prien EL, Babayan RK (December 1990). "Triamterene nephrolithiasis: renewed attention is warranted". The Journal of Urology. 144 (6): 1339–40. doi:10.1016/S0022-5347(17)39734-3. PMID 2231920.
  83. ^ McNutt WF (1893). "Section IV: Diseases of the Bladder, Chapter VII: Vesical Calculi (Cysto-lithiasis)". Diseases of the Kidneys and Bladder: A Text-Book for Students of Medicine. Philadelphia: J.B. Lippincott Company. pp. 185–6. from the original on 14 April 2021. Retrieved 6 November 2020.
  84. ^ a b c d e Gettman MT, Segura JW (March 2005). "Management of ureteric stones: issues and controversies". BJU International. 95 (Suppl 2): 85–93. doi:10.1111/j.1464-410X.2005.05206.x. PMID 15720341. S2CID 36265416.
  85. ^ Segura JW (February 1997). "Staghorn calculi". The Urologic Clinics of North America. 24 (1): 71–80. doi:10.1016/S0094-0143(05)70355-4. PMID 9048853.
  86. ^ a b Fink HA, Wilt TJ, Eidman KE, Garimella PS, MacDonald R, Rutks IR, Brasure M, Kane RL, Ouellette J, Monga M (April 2013). "Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline". Annals of Internal Medicine. 158 (7): 535–43. doi:10.7326/0003-4819-158-7-201304020-00005. PMID 23546565.
  87. ^ a b Qaseem A, Dallas P, Forciea MA, Starkey M, Denberg TD (November 2014). "Dietary and pharmacologic management to prevent recurrent nephrolithiasis in adults: a clinical practice guideline from the American College of Physicians". Annals of Internal Medicine. 161 (9): 659–67. doi:10.7326/m13-2908. PMID 25364887.
  88. ^ Goldfarb DS, Coe FL (November 1999). "Prevention of recurrent nephrolithiasis". American Family Physician. 60 (8): 2269–76. PMID 10593318. from the original on 22 August 2005.
  89. ^ a b Finkielstein VA, Goldfarb DS (May 2006). "Strategies for preventing calcium oxalate stones". CMAJ. 174 (10): 1407–9. doi:10.1503/cmaj.051517. PMC 1455427. PMID 16682705. from the original on 15 October 2008.
  90. ^ a b Fink HA, Wilt TJ, Eidman KE, Garimella PS, MacDonald R, Rutks IR, Brasure M, Kane RL, Monga M (July 2012). "Recurrent Nephrolithiasis in Adults: Comparative Effectiveness of Preventive Medical Strategies". Comparative Effectiveness Reviews (61). Rockvill, MD: Agency for Healthcare Research and Quality. PMID 22896859.
  91. ^ Ferraro PM, Taylor EN, Gambaro G, Curhan GC (August 2013). "Soda and other beverages and the risk of kidney stones". Clinical Journal of the American Society of Nephrology. 8 (8): 1389–95. doi:10.2215/CJN.11661112. PMC 3731916. PMID 23676355.
  92. ^ . kidney.org. Archived from the original on 14 May 2013. Retrieved 19 August 2013.
  93. ^ Taylor EN, Curhan GC (September 2006). "Diet and fluid prescription in stone disease". Kidney International. 70 (5): 835–9. doi:10.1038/sj.ki.5001656. PMID 16837923.
  94. ^ Gul Z, Monga M (December 2014). "Medical and dietary therapy for kidney stone prevention". Korean Journal of Urology. 55 (12): 775–9. doi:10.4111/kju.2014.55.12.775. PMC 4265710. PMID 25512810.
  95. ^ "Citric Acid and Kidney Stones" (PDF). uwhealth.org. (PDF) from the original on 5 July 2010.
  96. ^ Heaney RP (March 2006). "Nutrition and chronic disease". Mayo Clinic Proceedings. 81 (3): 297–9. doi:10.4065/81.3.297. PMID 16529131.
  97. ^ a b Tiselius HG (May 2003). "Epidemiology and medical management of stone disease". BJU International. 91 (8): 758–67. doi:10.1046/j.1464-410X.2003.04208.x. PMID 12709088. S2CID 28256459.
  98. ^ a b Taylor EN, Stampfer MJ, Curhan GC (December 2004). "Dietary factors and the risk of incident kidney stones in men: new insights after 14 years of follow-up" (PDF). Journal of the American Society of Nephrology. 15 (12): 3225–32. doi:10.1097/01.ASN.0000146012.44570.20. PMID 15579526. (PDF) from the original on 21 September 2017. Retrieved 3 June 2011.
  99. ^ Cicerello E, Merlo F, Maccatrozzo L (September 2010). "Urinary alkalization for the treatment of uric acid nephrolithiasis". Archivio Italiano di Urologia, Andrologia. 82 (3): 145–8. PMID 21121431.
  100. ^ "Effect of addition of calcium hydroxide to foods rich in oxalic acid on calcium and oxalic acid metabolism | Request PDF". from the original on 7 November 2021. Retrieved 6 March 2021.
  101. ^ Cameron JS, Simmonds HA (June 1987). "Use and abuse of allopurinol". British Medical Journal. 294 (6586): 1504–5. doi:10.1136/bmj.294.6586.1504. PMC 1246665. PMID 3607420.
  102. ^ Macaluso JN (November 1996). "Management of stone disease--bearing the burden". The Journal of Urology. 156 (5): 1579–80. doi:10.1016/S0022-5347(01)65452-1. PMID 8863542.
  103. ^ Pathan SA, Mitra B, Cameron PA (April 2018). "A Systematic Review and Meta-analysis Comparing the Efficacy of Nonsteroidal Anti-inflammatory Drugs, Opioids, and Paracetamol in the Treatment of Acute Renal Colic". European Urology. 73 (4): 583–595. doi:10.1016/j.eururo.2017.11.001. PMID 29174580.
  104. ^ a b c Seitz C, Liatsikos E, Porpiglia F, Tiselius HG, Zwergel U (September 2009). "Medical therapy to facilitate the passage of stones: what is the evidence?". European Urology. 56 (3): 455–71. doi:10.1016/j.eururo.2009.06.012. PMID 19560860.
  105. ^ a b c d e Campschroer T, Zhu X, Vernooij RW, Lock MT (April 2018). "Alpha-blockers as medical expulsive therapy for ureteral stones". The Cochrane Database of Systematic Reviews. 2018 (4): CD008509. doi:10.1002/14651858.CD008509.pub3. PMC 6494465. PMID 29620795.
  106. ^ a b c d e f g h i Shock Wave Lithotripsy Task Force (2009). (PDF). Clinical Guidelines. Linthicum, Maryland: American Urological Association. Archived from the original (PDF) on 18 July 2013. Retrieved 13 October 2015.
  107. ^ Lingeman JE, Matlaga BR, Evan AP (2007). "Surgical Management of Urinary Lithiasis". In Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (eds.). Campbell-Walsh Urology. Philadelphia: W. B. Saunders. pp. 1431–1507.
  108. ^ Preminger GM, Tiselius HG, Assimos DG, Alken P, Buck C, Gallucci M, Knoll T, Lingeman JE, Nakada SY, Pearle MS, Sarica K, Türk C, Wolf JS (December 2007). "2007 guideline for the management of ureteral calculi". The Journal of Urology. 178 (6): 2418–34. doi:10.1016/j.juro.2007.09.107. PMID 17993340.
  109. ^ a b Evan AP, McAteer JA (1996). "Ch. 28: Q-effects of Shock Wave Lithotripsy". In Coe FL, Favus MJ, Pak CY, Parks JH, Preminger GM (eds.). Kidney Stones: Medical and Surgical Management. Philadelphia: Lippincott-Raven. pp. 549–60. ISBN 978-0-7817-0263-8.
  110. ^ a b c Evan AP, Willis LR (2007). "Ch. 41: Extracorporeal Shock Wave Lithotripsy: Complications". In Smith AD, Badlani GH, Bagley DH, Clayman RV, Docimo SG (eds.). Smith's Textbook on Endourology. Hamilton, Ontario, Canada: B C Decker, Inc. pp. 353–65.
  111. ^ a b c Oestreich MC, Vernooij RW, Sathianathen NJ, Hwang EC, Kuntz GM, Koziarz A, Scales CD, Dahm P, et al. (Cochrane Urology Group) (November 2020). "Alpha-blockers after shock wave lithotripsy for renal or ureteral stones in adults". The Cochrane Database of Systematic Reviews. 2020 (11): CD013393. doi:10.1002/14651858.CD013393.pub2. PMC 8092672. PMID 33179245.
  112. ^ Young JG, Keeley FX, Ch. 38: "Indications for Surgical Removal, Including Asymptomatic Stones" in Rao, Preminger & Kavanagh 2011, pp. 441–454.
  113. ^ Wynberg JB, Borin JF, Vicena JZ, Hannosh V, Salmon SA (October 2012). "Flexible ureteroscopy-directed retrograde nephrostomy for percutaneous nephrolithotomy: description of a technique". Journal of Endourology. 26 (10): 1268–74. doi:10.1089/end.2012.0160. PMID 22563900.
  114. ^ Lam JS, Gupta M, Ch. 25: "Ureteral Stents". In Stoller & Meng 2007, pp. 465–83.
  115. ^ Ordonez M, Hwang EC, Borofsky M, Bakker CJ, Gandhi S, Dahm P, et al. (Cochrane Urology Group) (February 2019). "Ureteral stent versus no ureteral stent for ureteroscopy in the management of renal and ureteral calculi". The Cochrane Database of Systematic Reviews. 2019 (2): CD012703. doi:10.1002/14651858.CD012703.pub2. PMC 6365118. PMID 30726554.
  116. ^ Marks AJ, Qiu J, Milner TE, Chan KF, Teichman JM (6 January 2011), Ch. 26: "Laser Lithotripsy Physics", Springer, ISBN 978-1-84800-362-0, from the original on 20 February 2021, retrieved 6 November 2020 in Rao, Preminger & Kavanagh 2011, pp. 301–310.
  117. ^ a b c d Romero V, Akpinar H, Assimos DG (2010). "Kidney stones: a global picture of prevalence, incidence, and associated risk factors". Reviews in Urology. 12 (2–3): e86-96. PMC 2931286. PMID 20811557.
  118. ^ Lieske JC, Segura JW (2004). "Ch. 7: Evaluation and Medical Management of Kidney Stones". In Potts JM (ed.). Essential Urology: A Guide to Clinical Practice (1st ed.). Totowa, New Jersey: Humana Press. pp. 117–52. ISBN 978-1-58829-109-7.
  119. ^ Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA (December 2012). . Lancet. 380 (9859): 2095–128. doi:10.1016/S0140-6736(12)61728-0. hdl:10536/DRO/DU:30050819. PMC 10790329. PMID 23245604. S2CID 1541253. Archived from the original on 19 May 2020.
  120. ^ Windus D (2008). The Washington manual nephrology subspecialty consult (2nd ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins Health. p. 235. ISBN 978-0-7817-9149-6. from the original on 9 September 2016.
  121. ^ Glanvill J. Saducismus triumphatus, or, Full and plain evidence concerning witches and apparitions : in two parts, the first treating of their possibility, the second of their real existence. ISBN 1-171-33286-6. OCLC 943229347.
  122. ^ Celsus AC (1831). "Book VII, Chapter XXVI: Of the operation necessary in a suppression of urine, and lithotomy". In Collier GF (ed.). A translation of the eight books of Aul. Corn. Celsus on medicine (2nd ed.). London: Simpkin and Marshall. pp. 306–14. from the original on 8 July 2014.
  123. ^ a b Shah J, Whitfield HN (May 2002). "Urolithiasis through the ages". BJU International. 89 (8): 801–10. doi:10.1046/j.1464-410X.2002.02769.x. PMID 11972501. S2CID 44311421.
  124. ^ a b Ellis H (1969). A History of Bladder Stone. Oxford, England: Blackwell Scientific Publications. ISBN 978-0-632-06140-2.
  125. ^ Bigelow HJ (1878). Litholapaxy or rapid lithotrity with evacuation. Boston: A. Williams and Company. p. 29. from the original on 14 April 2021. Retrieved 25 August 2020.
  126. ^ Dwyer ME, Krambeck AE, Bergstralh EJ, Milliner DS, Lieske JC, Rule AD (July 2012). "Temporal trends in incidence of kidney stones among children: a 25-year population based study". The Journal of Urology. 188 (1): 247–52. doi:10.1016/j.juro.2012.03.021. PMC 3482509. PMID 22595060.
  127. ^ . Archived from the original on 17 November 2007. Retrieved 11 October 2013.
  128. ^ Kirejczyk JK, Porowski T, Filonowicz R, Kazberuk A, Stefanowicz M, Wasilewska A, Debek W (February 2014). "An association between kidney stone composition and urinary metabolic disturbances in children". Journal of Pediatric Urology. 10 (1): 130–5. doi:10.1016/j.jpurol.2013.07.010. PMID 23953243.
  129. ^ a b c Barreto L, Jung JH, Abdelrahim A, Ahmed M, Dawkins GP, Kazmierski M, et al. (Cochrane Urology Group) (June 2018). "Medical and surgical interventions for the treatment of urinary stones in children". The Cochrane Database of Systematic Reviews. 6 (6): CD010784. doi:10.1002/14651858.CD010784.pub2. PMC 6513049. PMID 29859007.
  130. ^ Aune D, Mahamat-Saleh Y, Norat T, Riboli E (November 2018). "Body fatness, diabetes, physical activity and risk of kidney stones: a systematic review and meta-analysis of cohort studies". European Journal of Epidemiology. 33 (11): 1033–1047. doi:10.1007/s10654-018-0426-4. PMC 6208979. PMID 30066054.
  131. ^ Trinchieri A, Croppi E, Montanari E (June 2017). "Obesity and urolithiasis: evidence of regional influences". Urolithiasis. 45 (3): 271–278. doi:10.1007/s00240-016-0908-3. PMID 27488444. S2CID 4585476.
  132. ^ Zisman AL (October 2017). "Effectiveness of Treatment Modalities on Kidney Stone Recurrence". Clinical Journal of the American Society of Nephrology. 12 (10): 1699–1708. doi:10.2215/cjn.11201016. PMC 5628726. PMID 28830863.
  133. ^ Stanford J, Charlton K, Stefoska-Needham A, Ibrahim R, Lambert K (5 June 2020). "The gut microbiota profile of adults with kidney disease and kidney stones: a systematic review of the literature". BMC Nephrology. 21 (1): 215. doi:10.1186/s12882-020-01805-w. ISSN 1471-2369. PMC 7275316. PMID 32503496.
  134. ^ Duncan SH, Richardson AJ, Kaul P, Holmes RP, Allison MJ, Stewart CS (1 August 2002). "Oxalobacter formigenes and Its Potential Role in Human Health". Applied and Environmental Microbiology. 68 (8): 3841–3847. Bibcode:2002ApEnM..68.3841D. doi:10.1128/AEM.68.8.3841-3847.2002. ISSN 0099-2240. PMC 124017. PMID 12147479.
  135. ^ Ticinesi A, Milani C, Guerra A, Allegri F, Lauretani F, Nouvenne A, Mancabelli L, Lugli GA, Turroni F, Duranti S, Mangifesta M (28 April 2018). "Understanding the gut–kidney axis in nephrolithiasis: an analysis of the gut microbiota composition and functionality of stone formers". Gut. 67 (12): 2097–2106. doi:10.1136/gutjnl-2017-315734. ISSN 0017-5749. PMID 29705728. S2CID 14055215.
  136. ^ Ramirez J, Guarner F, Bustos Fernandez L, Maruy A, Sdepanian VL, Cohen H (24 November 2020). "Antibiotics as Major Disruptors of Gut Microbiota". Frontiers in Cellular and Infection Microbiology. 10: 572912. doi:10.3389/fcimb.2020.572912. ISSN 2235-2988. PMC 7732679. PMID 33330122.
  137. ^ Tasian GE, Jemielita T, Goldfarb DS, Copelovitch L, Gerber JS, Wu Q, Denburg MR (1 June 2018). "Oral Antibiotic Exposure and Kidney Stone Disease". Journal of the American Society of Nephrology. 29 (6): 1731–1740. doi:10.1681/ASN.2017111213. ISSN 1046-6673. PMC 6054354. PMID 29748329.
  138. ^ a b c d e Pugh DG, Baird N (27 May 2012). Sheep & Goat Medicine - E-Book. Elsevier Health Sciences. ISBN 978-1-4377-2354-0. from the original on 14 April 2021. Retrieved 17 June 2018.
  139. ^ Bushman DH, Emerick RJ, Embry LB (December 1965). "Experimentally induced ovine phosphatic urolithiasis: relationships involving dietary calcium, phosphorus and magnesium". The Journal of Nutrition. 87 (4): 499–504. doi:10.1093/jn/87.4.499. PMID 5841867.
  140. ^ Stewart SR, Emerick RJ, Pritchard RH (May 1991). (PDF). Journal of Animal Science. 69 (5): 2225–9. doi:10.2527/1991.6952225x. PMID 1648554. S2CID 10130833. Archived from the original (PDF) on 2 March 2019.
  141. ^ Forman SA, Whiting F, Connell R (May 1959). "Silica Urolithiasis In Beef Cattle : 3. Chemical and Physical Composition of the Uroliths". Canadian Journal of Comparative Medicine and Veterinary Science. 23 (5): 157–62. PMC 1581990. PMID 17649146.
  142. ^ Scott D, Buchan W (May 1988). "The effects of feeding pelleted diets made from either coarsely or finely ground hay on phosphorus balance and on the partition of phosphorus excretion between urine and faeces in the sheep". Quarterly Journal of Experimental Physiology. 73 (3): 315–22. doi:10.1113/expphysiol.1988.sp003148. PMID 3399614.
  143. ^ Bravo D, Sauvant D, Bogaert C, Meschy F (2003). "III. Quantitative aspects of phosphorus excretion in ruminants" (PDF). Reproduction, Nutrition, Development. 43 (3): 285–300. doi:10.1051/rnd:2003021. PMID 14620634. (PDF) from the original on 16 April 2021. Retrieved 29 August 2019.
  144. ^ Waltner-Toews, D. and D. H. Meadows. 1980. Case report: Urolithiasis in a herd of beef cattle associated with oxalate ingestion. Can. Vet. J. 21: 61-62
  145. ^ James LF, Butcher JE (December 1972). "Halogeton poisoning of sheep: effect of high level oxalate intake". Journal of Animal Science. 35 (6): 1233–1238. doi:10.2527/jas1972.3561233x. PMID 4647453.
  146. ^ a b Kahn CM, ed. (2005). Merck veterinary manual (9th ed.). Whitehouse Station: Merck & Co., Inc.

Notes edit

  • Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Institute of Medicine of the National Academies (2011). Ross AC, Taylor CL, Yaktine AL, Del HB (eds.). Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press. doi:10.17226/13050. ISBN 978-0-309-16394-1. PMID 21796828. S2CID 58721779. from the original on 9 September 2014. Retrieved 21 June 2011.
  • Rao PN, Preminger GM, Kavanagh JP, eds. (2011). Urinary Tract Stone Disease (1st ed.). London: Springer-Verlag. doi:10.1007/978-1-84800-362-0_26. ISBN 978-1-84800-361-3.
  • Reilly RF, Perazella MA, eds. (2005). Nephrology in 30 Days (1st ed.). New York: The McGraw-Hill Companies, Inc. ISBN 978-0-07-143701-1. from the original on 14 April 2021. Retrieved 25 August 2020.
  • Stoller ML, Meng MV, eds. (2007). Urinary stone disease: the practical guide to medical and surgical management (1st ed.). Totowa, New Jersey: Humana Press. ISBN 978-1-59259-972-1.

External links edit

 
Wikimedia Commons has media related to Kidney stones.

January 01, 1970
kidney, stone, disease, also, known, renal, calculus, disease, nephrolithiasis, urolithiasis, crystallopathy, where, solid, piece, material, renal, calculus, develops, urinary, tract, renal, calculi, typically, form, kidney, leave, body, urine, stream, small, . Kidney stone disease also known as renal calculus disease nephrolithiasis or urolithiasis is a crystallopathy where a solid piece of material renal calculus develops in the urinary tract 2 Renal calculi typically form in the kidney and leave the body in the urine stream 2 A small calculus may pass without causing symptoms 2 If a stone grows to more than 5 millimeters 0 2 inches it can cause blockage of the ureter resulting in sharp and severe pain in the lower back that often radiates downward to the groin renal colic 2 7 A calculus may also result in blood in the urine vomiting or painful urination 2 About half of people who have had a renal calculus are likely to have another within ten years 8 Kidney stone diseaseOther namesUrolithiasis kidney stone renal calculus nephrolith kidney stone disease 1 A kidney stone 8 millimeters 0 3 in in diameterSpecialtyUrology nephrologySymptomsSevere pain in the lower back or abdomen blood in the urine vomiting nausea 2 CausesGenetic and environmental factors 2 Diagnostic methodBased on symptoms urine testing medical imaging 2 Differential diagnosisAbdominal aortic aneurysm diverticulitis appendicitis pyelonephritis 3 PreventionDrinking fluids such that more than two liters of urine are produced per day 4 TreatmentPain medication extracorporeal shock wave lithotripsy ureteroscopy percutaneous nephrolithotomy 2 Frequency22 1 million 2015 5 Deaths16 100 2015 6 Most calculi form by a combination of genetics and environmental factors 2 Risk factors include high urine calcium levels obesity certain foods some medications calcium supplements hyperparathyroidism gout and not drinking enough fluids 2 8 Calculi form in the kidney when minerals in urine are at high concentration 2 The diagnosis is usually based on symptoms urine testing and medical imaging 2 Blood tests may also be useful 2 Calculi are typically classified by their location nephrolithiasis in the kidney ureterolithiasis in the ureter cystolithiasis in the bladder or by what they are made of calcium oxalate uric acid struvite cystine 2 In those who have had renal calculi drinking fluids is a way to prevent them Drinking fluids such that more than two liters of urine are produced per day is recommended 4 If fluid intake alone is not effective to prevent renal calculi the medications thiazide diuretic citrate or allopurinol may be suggested 4 Soft drinks containing phosphoric acid typically colas should be avoided 4 When a calculus causes no symptoms no treatment is needed 2 For those with symptoms pain control is usually the first measure using medications such as nonsteroidal anti inflammatory drugs or opioids 7 9 Larger calculi may be helped to pass with the medication tamsulosin 10 or may require procedures such as extracorporeal shock wave lithotripsy ureteroscopy or percutaneous nephrolithotomy 2 Renal calculi have affected humans throughout history with a description of surgery to remove them dating from as early as 600 BC in ancient India by Sushruta 1 Between 1 and 15 of people globally are affected by renal calculi at some point in their lives 8 11 In 2015 22 1 million cases occurred 5 resulting in about 16 100 deaths 6 They have become more common in the Western world since the 1970s 8 12 Generally more men are affected than women 2 11 The prevalence and incidence of the disease rises worldwide and continues to be challenging for patients physicians and healthcare systems alike In this context epidemiological studies are striving to elucidate the worldwide changes in the patterns and the burden of the disease and identify modifiable risk factors that contribute to the development of renal calculi 13 Contents 1 Signs and symptoms 2 Risk factors 2 1 Calcium oxalate 2 2 Other electrolytes 2 3 Animal protein 2 4 Vitamins 3 Pathophysiology 3 1 Supersaturation of urine 3 2 Randall s plaque 3 3 Pathogenic bacteria 3 4 Inhibitors of stone formation 3 5 Hypocitraturia 4 Diagnosis 4 1 Imaging studies 4 2 Laboratory examination 4 3 Composition 4 3 1 Calcium containing stones 4 3 2 Struvite stones 4 3 3 Uric acid stones 4 3 4 Other types 4 4 Location 4 5 Size 5 Prevention 5 1 Dietary measures 5 2 Urine alkalinization 5 2 1 Slaked lime 5 3 Diuretics 5 4 Allopurinol 6 Treatment 6 1 Pain management 6 2 Medical expulsive therapy 6 3 Lithotripsy 6 4 Surgery 6 4 1 Ureteroscopic surgery 7 Epidemiology 8 History 8 1 Etymology 9 Children 10 Research 10 1 Gut microbiota 11 In animals 12 See also 13 References 13 1 Notes 14 External linksSigns and symptoms edit nbsp Diagram showing the typical location of renal colic below the rib cage to just above the pelvis The hallmark of a stone that obstructs the ureter or renal pelvis is excruciating intermittent pain that radiates from the flank to the groin or to the inner thigh 14 This is due to the transfer of referred pain signals from the lower thoracic splanchnic nerves to the lumbar splanchnic nerves as the stone passes down from the kidney or proximal ureter to the distal ureter This pain known as renal colic is often described as one of the strongest pain sensations known 15 Renal colic caused by kidney stones is commonly accompanied by urinary urgency restlessness hematuria sweating nausea and vomiting It typically comes in waves lasting 20 to 60 minutes caused by peristaltic contractions of the ureter as it attempts to expel the stone 14 The embryological link between the urinary tract the genital system and the gastrointestinal tract is the basis of the radiation of pain to the gonads as well as the nausea and vomiting that are also common in urolithiasis 16 Postrenal azotemia and hydronephrosis can be observed following the obstruction of urine flow through one or both ureters 17 Pain in the lower left quadrant can sometimes be confused with diverticulitis because the sigmoid colon overlaps the ureter and the exact location of the pain may be difficult to isolate due to the proximity of these two structures Risk factors editDehydration from low fluid intake is a major factor in stone formation 14 18 Individuals living in warm climates are at higher risk due to increased fluid loss 19 Obesity immobility and sedentary lifestyles are other leading risk factors 19 High dietary intake of animal protein 14 sodium sugars including honey refined sugars fructose and high fructose corn syrup 20 and excessive consumption of fruit juices may increase the risk of kidney stone formation due to increased uric acid excretion and elevated urinary oxalate levels whereas tea coffee wine and beer may decrease the risk 19 18 Kidney stones can result from an underlying metabolic condition such as distal renal tubular acidosis 21 Dent s disease 22 hyperparathyroidism 23 primary hyperoxaluria 24 or medullary sponge kidney 3 20 of people who form kidney stones have medullary sponge kidney 25 26 Kidney stones are more common in people with Crohn s disease 27 Crohn s disease is associated with hyperoxaluria and malabsorption of magnesium 28 A person with recurrent kidney stones may be screened for such disorders This is typically done with a 24 hour urine collection The urine is analyzed for features that promote stone formation 17 Calcium oxalate edit nbsp A kidney stone yellow composed of calcium oxalateCalcium is one component of the most common type of human kidney stones calcium oxalate Some studies suggest that people who take calcium or vitamin D as a dietary supplement have a higher risk of developing kidney stones 29 30 In the United States kidney stone formation was used as an indicator of excess calcium intake by the Reference Daily Intake committee for calcium in adults 31 In the early 1990s a study conducted for the Women s Health Initiative in the US found that postmenopausal women who consumed 1000 mg of supplemental calcium and 400 international units of vitamin D per day for seven years had a 17 higher risk of developing kidney stones than subjects taking a placebo 29 The Nurses Health Study also showed an association between supplemental calcium intake and kidney stone formation 30 Unlike supplemental calcium high intakes of dietary calcium do not appear to cause kidney stones and may actually protect against their development 30 29 This is perhaps related to the role of calcium in binding ingested oxalate in the gastrointestinal tract As the amount of calcium intake decreases the amount of oxalate available for absorption into the bloodstream increases this oxalate is then excreted in greater amounts into the urine by the kidneys In the urine oxalate is a very strong promoter of calcium oxalate precipitation about 15 times stronger than calcium A 2004 study found that diets low in calcium are associated with a higher overall risk for kidney stone formation 32 For most individuals other risk factors for kidney stones such as high intakes of dietary oxalates and low fluid intake play a greater role than calcium intake 33 Other electrolytes edit Calcium is not the only electrolyte that influences the formation of kidney stones For example by increasing urinary calcium excretion high dietary sodium may increase the risk of stone formation 30 Drinking fluoridated tap water may increase the risk of kidney stone formation by a similar mechanism though further epidemiologic studies are warranted to determine whether fluoride in drinking water is associated with an increased incidence of kidney stones 34 High dietary intake of potassium appears to reduce the risk of stone formation because potassium promotes the urinary excretion of citrate an inhibitor of calcium crystal formation 35 Kidney stones are more likely to develop and to grow larger if a person has low dietary magnesium Magnesium inhibits stone formation 36 Animal protein edit Diets in Western nations typically contain a large proportion of animal protein Eating animal protein creates an acid load that increases urinary excretion of calcium and uric acid and reduced citrate Urinary excretion of excess sulfurous amino acids e g cysteine and methionine uric acid and other acidic metabolites from animal protein acidifies the urine which promotes the formation of kidney stones 37 Low urinary citrate excretion is also commonly found in those with a high dietary intake of animal protein whereas vegetarians tend to have higher levels of citrate excretion 30 Low urinary citrate too promotes stone formation 37 Vitamins edit The evidence linking vitamin C supplements with an increased rate of kidney stones is inconclusive 38 39 The excess dietary intake of vitamin C might increase the risk of calcium oxalate stone formation 40 The link between vitamin D intake and kidney stones is also tenuous Excessive vitamin D supplementation may increase the risk of stone formation by increasing the intestinal absorption of calcium correction of a deficiency does not 30 Pathophysiology edit nbsp Small crystals formed in the kidney The most common crystals are made of calcium oxalate and they are generally 4 5 mm Staghorn kidney stones are considerably larger 1 Calcium and oxalate come together to make the crystal nucleus Supersaturation promotes their combination as does inhibition 2 Continued deposition at the renal papillae leads to the growth of the kidney stones 3 Kidney stones grow and collect debris In the case where the kidney stones block all routes to the renal papillae this can cause extreme discomfort and pain 4 The complete staghorn stone forms and retention occurs Smaller solids that break off can become trapped in the urinary glands causing discomfort 5 Displaced stones travel through the ureter If they cannot be broken down they must be physically removed by a surgeon Supersaturation of urine edit When the urine becomes supersaturated when the urine solvent contains more solutes than it can hold in solution with one or more calculogenic crystal forming substances a seed crystal may form through the process of nucleation 25 Heterogeneous nucleation where there is a solid surface present on which a crystal can grow proceeds more rapidly than homogeneous nucleation where a crystal must grow in a liquid medium with no such surface because it requires less energy Adhering to cells on the surface of a renal papilla a seed crystal can grow and aggregate into an organized mass Depending on the chemical composition of the crystal the stone forming process may proceed more rapidly when the urine pH is unusually high or low 41 Supersaturation of the urine with respect to a calculogenic compound is pH dependent For example at a pH of 7 0 the solubility of uric acid in urine is 158 mg 100 mL Reducing the pH to 5 0 decreases the solubility of uric acid to less than 8 mg 100 mL The formation of uric acid stones requires a combination of hyperuricosuria high urine uric acid levels and low urine pH hyperuricosuria alone is not associated with uric acid stone formation if the urine pH is alkaline 42 Supersaturation of the urine is a necessary but not a sufficient condition for the development of any urinary calculus 25 Supersaturation is likely the underlying cause of uric acid and cystine stones but calcium based stones especially calcium oxalate stones may have a more complex cause 43 Randall s plaque edit While supersaturation of urine may lead to crystalluria it does not necessarily promote the formation of a kidney stone because the particle may not reach the sufficient size needed for renal attachment 44 45 On the other hand Randall s plaques which were first identified by Alexander Randall in 1937 46 are calcium phosphate deposits that form in the papillary interstitium and are thought to be the nidus required for stone development 47 In addition to Randall s plugs which form in the Duct of Bellini these structures can generate reactive oxygen species that further enhance stone formation 48 Pathogenic bacteria edit Some bacteria have roles in promoting stone formation Specifically urease positive bacteria such as Proteus mirabilis can produce the enzyme urease which converts urea to ammonia and carbon dioxide 49 This increases the urinary pH and promotes struvite stone formation Additionally non urease producing bacteria can provide bacteria components that can promote calcium oxalate crystallization though this mechanism is poorly understood 50 51 Inhibitors of stone formation edit Normal urine contains chelating agents such as citrate that inhibit the nucleation growth and aggregation of calcium containing crystals Other endogenous inhibitors include calgranulin an S 100 calcium binding protein Tamm Horsfall protein glycosaminoglycans uropontin a form of osteopontin nephrocalcin an acidic glycoprotein prothrombin F1 peptide and bikunin uronic acid rich protein The biochemical mechanisms of action of these substances have not yet been thoroughly elucidated However when these substances fall below their normal proportions stones can form from an aggregation of crystals 52 Sufficient dietary intake of magnesium and citrate inhibits the formation of calcium oxalate and calcium phosphate stones in addition magnesium and citrate operate synergistically to inhibit kidney stones The efficacy of magnesium in subduing stone formation and growth is dose dependent 30 36 53 Hypocitraturia edit Hypocitraturia or low urinary citrate excretion variably defined as less than 320 mg day can be a contributing cause of kidney stones in up to 2 3 of cases The protective role of citrate is linked to several mechanisms citrate reduces urinary supersaturation of calcium salts by forming soluble complexes with calcium ions and by inhibiting crystal growth and aggregation Therapy with potassium citrate is commonly prescribed in clinical practice to increase urinary citrate and to reduce stone formation rates Alkali citrate is also used to increase urine citrate levels It can be prescribed or found over the counter in pill liquid or powder form 54 55 Diagnosis editDiagnosis of kidney stones is made on the basis of information obtained from the history physical examination urinalysis and radiographic studies 56 Clinical diagnosis is usually made on the basis of the location and severity of the pain which is typically colicky in nature comes and goes in spasmodic waves Pain in the back occurs when calculi produce an obstruction in the kidney 57 Physical examination may reveal fever and tenderness at the costovertebral angle on the affected side 56 Imaging studies edit Calcium containing stones are relatively radiodense opaque to X rays and they can often be detected by a traditional radiography of the abdomen that includes the kidneys ureters and bladder KUB film clarification needed 58 KUB clarification needed radiography although useful in monitoring size of stone or passage of stone in stone formers might not be useful in the acute setting due to low sensitivity 59 Some 60 of all renal stones are radiopaque 60 61 In general calcium phosphate stones have the greatest density followed by calcium oxalate and magnesium ammonium phosphate stones Cystine calculi are only faintly radiodense while uric acid stones are usually entirely radiolucent 62 In people with a history of stones those who are less than 50 years of age and are presenting with the symptoms of stones without any concerning signs do not require helical CT scan imaging 63 A computed tomography CT scan is also not typically recommended in children 64 Otherwise a noncontrast helical CT scan with 5 millimeters 0 2 in sections is the diagnostic method to use to detect kidney stones and confirm the diagnosis of kidney stone disease 16 56 60 65 7 Near all stones are detectable on CT scans with the exception of those composed of certain drug residues in the urine 58 such as from indinavir Where a CT scan is unavailable an intravenous pyelogram may be performed to help confirm the diagnosis of urolithiasis This involves intravenous injection of a contrast agent followed by a KUB film Uroliths present in the kidneys ureters or bladder may be better defined by the use of this contrast agent Stones can also be detected by a retrograde pyelogram where a similar contrast agent is injected directly into the distal ostium of the ureter where the ureter terminates as it enters the bladder 60 Renal ultrasonography can sometimes be useful because it gives details about the presence of hydronephrosis suggesting that the stone is blocking the outflow of urine 58 Radiolucent stones which do not appear on KUB may show up on ultrasound imaging studies Other advantages of renal ultrasonography include its low cost and absence of radiation exposure Ultrasound imaging is useful for detecting stones in situations where X rays or CT scans are discouraged such as in children or pregnant women 66 Despite these advantages renal ultrasonography in 2009 was not considered a substitute for noncontrast helical CT scan in the initial diagnostic evaluation of urolithiasis 65 The main reason for this is that compared with CT renal ultrasonography more often fails to detect small stones especially ureteral stones and other serious disorders that could be causing the symptoms 14 On the contrary a 2014 study suggested that ultrasonography should be used as the initial diagnostic imaging test with further imaging studies be performed at the discretion of the physician on the basis of clinical judgment and using ultrasonography rather than CT as an initial diagnostic test results in less radiation exposure and equally good outcome 67 nbsp Bilateral kidney stones can be seen on this KUB radiograph There are phleboliths in the pelvis which can be misinterpreted as bladder stones nbsp Axial CT scan of abdomen without contrast showing a 3 mm stone marked by an arrow in the left proximal ureter nbsp Renal ultrasonograph of a stone located at the pyeloureteric junction with accompanying hydronephrosis nbsp Measurement of a 5 6 mm large kidney stone in soft tissue versus skeletal CT window Laboratory examination edit nbsp Struvite crystals found on microscopic examination of the urine Laboratory investigations typically carried out include 56 65 58 68 microscopic examination of the urine which may show red blood cells bacteria leukocytes urinary casts and crystals urine culture to identify any infecting organisms present in the urinary tract and sensitivity to determine the susceptibility of these organisms to specific antibiotics complete blood count looking for neutrophilia increased neutrophil granulocyte count suggestive of bacterial infection as seen in the setting of struvite stones renal function tests to look for abnormally high blood calcium levels hypercalcemia 24 hour urine collection to measure total daily urinary volume magnesium sodium uric acid calcium citrate oxalate and phosphate collection of stones by urinating through a StoneScreen kidney stone collection cup or a simple tea strainer is useful Chemical analysis of collected stones can establish their composition which in turn can help to guide future preventive and therapeutic management Composition edit Kidney stone type Relative incidence adults 69 Circumstances Color and microscopy appearance Radio density Details Calcium oxalate 60 when urine is acidic decreased pH 70 Black dark brown nbsp Radio opaque Some of the oxalate in urine is produced by the body Calcium and oxalate in the diet play a part but are not the only factors that affect the formation of calcium oxalate stones Dietary oxalate is found in many vegetables fruits and nuts Calcium from bone may also play a role in kidney stone formation Calcium phosphate 10 20 when urine is alkaline high pH Dirty white nbsp Radio opaque Tends to grow in alkaline urine especially when Proteus bacteria are present The most common type among pregnant women 69 Uric acid 10 20 when urine is persistently acidic Yellow reddish brown nbsp Radiolucent Diets rich in animal proteins and purines substances found naturally in all food but especially in organ meats fish and shellfish Struvite 3 infections in the kidney and when urine is alkaline high pH Dirty white nbsp Radio opaque Prevention of struvite stones depends on staying infection free Diet has not been shown to affect struvite stone formation Cystine 1 2 71 rare genetic disorder Pink yellow nbsp Radio opaque Cystine an amino acid a dimer of cysteine of the building blocks of protein leaks through the kidneys and into the urine to form crystals Xanthine 72 extremely rare Brick red Radiolucent nbsp Scanning electron micrograph of the surface of a kidney stone showing tetragonal crystals of weddellite calcium oxalate dihydrate emerging from the amorphous central part of the stone the horizontal length of the picture represents 0 5 mm of the figured original nbsp Multiple kidney stones composed of uric acid and a small amount of calcium oxalate nbsp A lenticular kidney stone excreted in the urine Calcium containing stones edit By far the most common type of kidney stones worldwide contains calcium For example calcium containing stones represent about 80 of all cases in the United States these typically contain calcium oxalate either alone or in combination with calcium phosphate in the form of apatite or brushite 25 52 Factors that promote the precipitation of oxalate crystals in the urine such as primary hyperoxaluria are associated with the development of calcium oxalate stones 24 The formation of calcium phosphate stones is associated with conditions such as hyperparathyroidism 23 and renal tubular acidosis 73 Oxaluria is increased in patients with certain gastrointestinal disorders including inflammatory bowel disease such as Crohn s disease or in patients who have undergone resection of the small bowel or small bowel bypass procedures Oxaluria is also increased in patients who consume increased amounts of oxalate found in vegetables and nuts Primary hyperoxaluria is a rare autosomal recessive condition that usually presents in childhood 74 Calcium oxalate crystals can come in two varieties Calcium oxalate monohydrate can appear as dumbbells or as long ovals that resemble the individual posts in a picket fence Calcium oxalate dihydrate have a tetragonal envelope appearance 74 Struvite stones edit About 10 15 of urinary calculi are composed of struvite hexa hydrated ammonium magnesium phosphate NH4MgPO4 6H2O 75 Struvite stones also known as infection stones urease or triple phosphate stones form most often in the presence of infection by urea splitting bacteria Using the enzyme urease these organisms metabolize urea into ammonia and carbon dioxide This alkalinizes the urine resulting in favorable conditions for the formation of struvite stones Proteus mirabilis Proteus vulgaris and Morganella morganii are the most common organisms isolated less common organisms include Ureaplasma urealyticum and some species of Providencia Klebsiella Serratia and Enterobacter These infection stones are commonly observed in people who have factors that predispose them to urinary tract infections such as those with spinal cord injury and other forms of neurogenic bladder ileal conduit urinary diversion vesicoureteral reflux and obstructive uropathies They are also commonly seen in people with underlying metabolic disorders such as idiopathic hypercalciuria hyperparathyroidism and gout Infection stones can grow rapidly forming large calyceal staghorn antler shaped calculi requiring invasive surgery such as percutaneous nephrolithotomy for definitive treatment 75 Struvite stones triple phosphate magnesium ammonium phosphate have a coffin lid morphology by microscopy 74 Uric acid stones edit About 5 10 of all stones are formed from uric acid 21 People with certain metabolic abnormalities including obesity 30 may produce uric acid stones They also may form in association with conditions that cause hyperuricosuria an excessive amount of uric acid in the urine with or without hyperuricemia an excessive amount of uric acid in the serum They may also form in association with disorders of acid base metabolism where the urine is excessively acidic low pH resulting in precipitation of uric acid crystals A diagnosis of uric acid urolithiasis is supported by the presence of a radiolucent stone in the face of persistent urine acidity in conjunction with the finding of uric acid crystals in fresh urine samples 76 As noted above section on calcium oxalate stones people with inflammatory bowel disease Crohn s disease ulcerative colitis tend to have hyperoxaluria and form oxalate stones They also have a tendency to form urate stones Urate stones are especially common after colon resection Uric acid stones appear as pleomorphic crystals usually diamond shaped They may also look like squares or rods which are polarizable 74 Other types edit People with certain rare inborn errors of metabolism have a propensity to accumulate crystal forming substances in their urine For example those with cystinuria cystinosis and Fanconi syndrome may form stones composed of cystine Cystine stone formation can be treated with urine alkalinization and dietary protein restriction People affected by xanthinuria often produce stones composed of xanthine People affected by adenine phosphoribosyltransferase deficiency may produce 2 8 dihydroxyadenine stones 77 alkaptonurics produce homogentisic acid stones and iminoglycinurics produce stones of glycine proline and hydroxyproline 78 79 Urolithiasis has also been noted to occur in the setting of therapeutic drug use with crystals of drug forming within the renal tract in some people currently being treated with agents such as indinavir 80 sulfadiazine 81 and triamterene 82 Location edit nbsp Illustration of kidney stones Urolithiasis refers to stones originating anywhere in the urinary system including the kidneys and bladder 16 Nephrolithiasis refers to the presence of such stones in the kidneys Calyceal calculi are aggregations in either the minor or major calyx parts of the kidney that pass urine into the ureter the tube connecting the kidneys to the urinary bladder The condition is called ureterolithiasis when a calculus is located in the ureter Stones may also form or pass into the bladder a condition referred to as bladder stones 83 Size edit nbsp Radiograph showing a large staghorn calculus involving the major calyces and renal pelvis in a person with severe scoliosis Stones less than 5 mm 0 2 in in diameter pass spontaneously in up to 98 of cases while those measuring 5 to 10 mm 0 2 to 0 4 in in diameter pass spontaneously in less than 53 of cases 84 Stones that are large enough to fill out the renal calyces are called staghorn stones and are composed of struvite in a vast majority of cases which forms only in the presence of urease forming bacteria Other forms that can possibly grow to become staghorn stones are those composed of cystine calcium oxalate monohydrate and uric acid 85 Prevention editPreventative measures depend on the type of stones In those with calcium stones drinking plenty of fluids thiazide diuretics and citrate are effective as is allopurinol in those with high uric acid levels in urine 86 87 Dietary measures edit See also Hypocitraturia Specific therapy should be tailored to the type of stones involved Diet can have an effect on the development of kidney stones Preventive strategies include some combination of dietary modifications and medications with the goal of reducing the excretory load of calculogenic compounds on the kidneys 32 88 89 Dietary recommendations to minimize the formation of kidney stones include increasing total fluid intake to achieve more than two liters per day of urine output 90 limiting cola including sugar sweetened soft drinks 86 90 91 to less than one liter per week 92 limiting animal protein intake to no more than two meals daily an association between animal protein and recurrence of kidney stones has been shown in men 93 increasing citrate or alkali intake including from lemon and lime juice 94 Citric acid in its natural form such as from citrus fruits prevents small stones from becoming problem stones by coating them and preventing other material from attaching and building onto the stones 95 reducing sodium intake is associated with a reduction in urine calcium excretion Maintenance of dilute urine by means of vigorous fluid therapy is beneficial in all forms of kidney stones so increasing urine volume is a key principle for the prevention of kidney stones Fluid intake should be sufficient to maintain a urine output of at least 2 litres 68 US fl oz per day 87 A high fluid intake may reduce the likelihood of kidney stone recurrence or may increase the time between stone development without unwanted effects Calcium binds with available oxalate in the gastrointestinal tract thereby preventing its absorption into the bloodstream Reducing oxalate absorption decreases kidney stone risk in susceptible people 96 Because of this some doctors recommend increasing dairy intake so that its calcium content will serve as an oxalate binder Taking calcium citrate tablets during or after meals containing high oxalate foods 97 may be useful if dietary calcium cannot be increased by other means as in those with lactose intolerance The preferred calcium supplement for people at risk of stone formation is calcium citrate as opposed to calcium carbonate because it helps to increase urinary citrate excretion 89 Aside from vigorous oral hydration and eating more dietary calcium other prevention strategies include avoidance of higher doses of supplemental vitamin C since ascorbate is metabolized to oxalate and restriction of oxalate rich foods such as leaf vegetables rhubarb soy products and chocolate 98 However no randomized controlled trial of oxalate restriction has been performed to test the hypothesis that oxalate restriction reduces stone formation 97 Some evidence indicates magnesium intake decreases the risk of symptomatic kidney stones 98 Urine alkalinization edit The mainstay for medical management of uric acid stones is alkalinization increasing the pH of the urine Uric acid stones are among the few types amenable to dissolution therapy referred to as chemolysis Chemolysis is usually achieved through the use of oral medications although in some cases intravenous agents or even instillation of certain irrigating agents directly onto the stone can be performed using antegrade nephrostomy or retrograde ureteral catheters 42 Acetazolamide is a medication that alkalinizes the urine In addition to acetazolamide or as an alternative certain dietary supplements are available that produce a similar alkalinization of the urine These include alkali citrate sodium bicarbonate potassium citrate magnesium citrate and bicitrate a combination of citric acid monohydrate and sodium citrate dihydrate 99 Aside from alkalinization of the urine these supplements have the added advantage of increasing the urinary citrate level which helps to reduce the aggregation of calcium oxalate stones 42 Increasing the urine pH to around 6 5 provides optimal conditions for dissolution of uric acid stones Increasing the urine pH to a value higher than 7 0 may increase the risk of calcium phosphate stone formation though this concept is controversial since citrate does inhibit calcium phosphate crystallization Testing the urine periodically with nitrazine paper can help to ensure the urine pH remains in this optimal range Using this approach stone dissolution rate can be expected to be around 10 mm 0 4 in of stone radius per month 42 Slaked lime edit Calcium hydroxide decreases urinary calcium when combined with food rich in oxalic acid such as green leafy vegetables 100 Diuretics edit One of the recognized medical therapies for prevention of stones is the thiazide and thiazide like diuretics such as chlorthalidone or indapamide These drugs inhibit the formation of calcium containing stones by reducing urinary calcium excretion 14 Sodium restriction is necessary for clinical effect of thiazides as sodium excess promotes calcium excretion Thiazides work best for renal leak hypercalciuria high urine calcium levels a condition in which high urinary calcium levels are caused by a primary kidney defect Thiazides are useful for treating absorptive hypercalciuria a condition in which high urinary calcium is a result of excess absorption from the gastrointestinal tract 52 Allopurinol edit For people with hyperuricosuria and calcium stones allopurinol is one of the few treatments that have been shown to reduce kidney stone recurrences Allopurinol interferes with the production of uric acid in the liver The drug is also used in people with gout or hyperuricemia high serum uric acid levels 101 Dosage is adjusted to maintain a reduced urinary excretion of uric acid Serum uric acid level at or below 6 mg 100 mL is often a therapeutic goal Hyperuricemia is not necessary for the formation of uric acid stones hyperuricosuria can occur in the presence of normal or even low serum uric acid Some practitioners advocate adding allopurinol only in people in whom hyperuricosuria and hyperuricemia persist despite the use of a urine alkalinizing agent such as sodium bicarbonate or potassium citrate 42 Treatment editStone size influences the rate of spontaneous stone passage For example up to 98 of small stones less than 5 mm 0 2 in in diameter may pass spontaneously through urination within four weeks of the onset of symptoms 7 but for larger stones 5 to 10 mm 0 2 to 0 4 in in diameter the rate of spontaneous passage decreases to less than 53 84 Initial stone location also influences the likelihood of spontaneous stone passage Rates increase from 48 for stones located in the proximal ureter to 79 for stones located at the vesicoureteric junction regardless of stone size 84 Assuming no high grade obstruction or associated infection is found in the urinary tract and symptoms are relatively mild various nonsurgical measures can be used to encourage the passage of a stone 42 Repeat stone formers benefit from more intense management including proper fluid intake and use of certain medications as well as careful monitoring 102 Pain management edit Management of pain often requires intravenous administration of NSAIDs or opioids 14 NSAIDs appear somewhat better than opioids or paracetamol in those with normal kidney function 103 Medications by mouth are often effective for less severe discomfort 66 The use of antispasmodics does not have further benefit 9 Medical expulsive therapy edit The use of medications to speed the spontaneous passage of stones in the ureter is referred to as medical expulsive therapy 104 105 Several agents including alpha adrenergic blockers such as tamsulosin and calcium channel blockers such as nifedipine may be effective 104 Alpha blockers likely result in more people passing their stones and they may pass their stones in a shorter time 105 People taking alpha blockers may also use less pain medication and may not need to visit the hospital 105 Alpha blockers appear to be more effective for larger stones over 5 mm in size than smaller stones 105 However use of alpha blockers may be associated with a slight increase in serious unwanted effects from this medication 105 A combination of tamsulosin and a corticosteroid may be better than tamsulosin alone 104 These treatments also appear to be useful in addition to lithotripsy 7 Lithotripsy edit nbsp A lithotriptor machine with a mobile fluoroscopic system C arm is seen in an operating room other equipment is seen in the background including an anesthesia machine Extracorporeal shock wave lithotripsy ESWL is a noninvasive technique for the removal of kidney stones Most ESWL is carried out when the stone is present near the renal pelvis ESWL involves the use of a lithotriptor machine to deliver externally applied focused high intensity pulses of ultrasonic energy to cause fragmentation of a stone over a period of around 30 60 minutes Following its introduction in the United States in February 1984 ESWL was rapidly and widely accepted as a treatment alternative for renal and ureteral stones 106 It is currently used in the treatment of uncomplicated stones located in the kidney and upper ureter provided the aggregate stone burden stone size and number is less than 20 mm 0 8 in and the anatomy of the involved kidney is normal 107 108 For a stone greater than 10 millimetres 0 39 in ESWL may not help break the stone in one treatment instead two or three treatments may be needed Some 80 85 of simple renal calculi can be effectively treated with ESWL 7 A number of factors can influence its efficacy including chemical composition of the stone presence of anomalous renal anatomy and the specific location of the stone within the kidney presence of hydronephrosis body mass index and distance of the stone from the surface of the skin 106 Common adverse effects of ESWL include acute trauma such as bruising at the site of shock administration and damage to blood vessels of the kidney 109 110 In fact the vast majority of people who are treated with a typical dose of shock waves using currently accepted treatment settings are likely to experience some degree of acute kidney injury 106 ESWL induced acute kidney injury is dose dependent increases with the total number of shock waves administered and with the power setting of the lithotriptor and can be severe 106 including internal bleeding and subcapsular hematomas On rare occasions such cases may require blood transfusion and even lead to acute kidney failure Hematoma rates may be related to the type of lithotriptor used hematoma rates of less than 1 and up to 13 have been reported for different lithotriptor machines 110 Recent studies show reduced acute tissue injury when the treatment protocol includes a brief pause following the initiation of treatment and both improved stone breakage and a reduction in injury when ESWL is carried out at slow shock wave rate 106 In addition to the aforementioned potential for acute kidney injury animal studies suggest these acute injuries may progress to scar formation resulting in loss of functional renal volume 109 110 Recent prospective studies also indicate elderly people are at increased risk of developing new onset hypertension following ESWL In addition a retrospective case control study published by researchers from the Mayo Clinic in 2006 has found an increased risk of developing diabetes mellitus and hypertension in people who had undergone ESWL compared with age and gender matched people who had undergone nonsurgical treatment Whether or not acute trauma progresses to long term effects probably depends on multiple factors that include the shock wave dose i e the number of shock waves delivered rate of delivery power setting acoustic characteristics of the particular lithotriptor and frequency of retreatment as well as certain intrinsic predisposing pathophysiologic risk factors 106 To address these concerns the American Urological Association established the Shock Wave Lithotripsy Task Force to provide an expert opinion on the safety and risk benefit ratio of ESWL The task force published a white paper outlining their conclusions in 2009 They concluded the risk benefit ratio remains favorable for many people 106 The advantages of ESWL include its noninvasive nature the fact that it is technically easy to treat most upper urinary tract calculi and that at least acutely it is a well tolerated low morbidity treatment for the vast majority of people However they recommended slowing the shock wave firing rate from 120 pulses per minute to 60 pulses per minute to reduce the risk of renal injury and increase the degree of stone fragmentation 106 Alpha blockers are sometimes prescribed after shock wave lithotripsy to help the pieces of the stone leave the person s body 111 By relaxing muscles and helping to keep blood vessels open alpha blockers may relax the ureter muscles to allow the kidney stone fragments to pass When compared to usual care or placebo treatment alpha blockers may lead to faster clearing of stones a reduced need for extra treatment and fewer unwanted effects 111 They may also clear kidney stones in more adults than the standard shock wave lithotripsy procedure The unwanted effects associated with alpha blockers are hospital emergency visits and return to hospital for stone related issues but these effects were more common in adults who did not receive alpha blockers as a part of their treatment 111 Surgery edit nbsp Three dimensional reconstructed CT scan image of a ureteral stent in the left kidney indicated by yellow arrow with a kidney stone in the inferior renal pelvis highest red arrow and one in the ureter beside the stent lower red arrow nbsp A kidney stone at the tip of an ultrasonic stone disintegration apparatus Most stones under 5 mm 0 2 in pass spontaneously 32 7 Prompt surgery may nonetheless be required in persons with only one working kidney bilateral obstructing stones a urinary tract infection and thus it is presumed an infected kidney or intractable pain 112 Beginning in the mid 1980s less invasive treatments such as extracorporeal shock wave lithotripsy ureteroscopy and percutaneous nephrolithotomy began to replace open surgery as the modalities of choice for the surgical management of urolithiasis 7 More recently flexible ureteroscopy has been adapted to facilitate retrograde nephrostomy creation for percutaneous nephrolithotomy This approach is still under investigation though early results are favorable 113 Percutaneous nephrolithotomy or rarely anatrophic nephrolithotomy is the treatment of choice for large or complicated stones such as calyceal staghorn calculi or stones that cannot be extracted using less invasive procedures 56 7 Ureteroscopic surgery edit Ureteroscopy has become increasingly popular as flexible and rigid fiberoptic ureteroscopes have become smaller One ureteroscopic technique involves the placement of a ureteral stent a small tube extending from the bladder up the ureter and into the kidney to provide immediate relief of an obstructed kidney Stent placement can be useful for saving a kidney at risk for postrenal acute kidney failure due to the increased hydrostatic pressure swelling and infection pyelonephritis and pyonephrosis caused by an obstructing stone Ureteral stents vary in length from 24 to 30 cm 9 4 to 11 8 in and most have a shape commonly referred to as a double J or double pigtail because of the curl at both ends They are designed to allow urine to flow past an obstruction in the ureter They may be retained in the ureter for days to weeks as infections resolve and as stones are dissolved or fragmented by ESWL or by some other treatment The stents dilate the ureters which can facilitate instrumentation and they also provide a clear landmark to aid in the visualization of the ureters and any associated stones on radiographic examinations The presence of indwelling ureteral stents may cause minimal to moderate discomfort frequency or urgency incontinence and infection which in general resolves on removal Most ureteral stents can be removed cystoscopically during an office visit under topical anesthesia after resolution of urolithiasis 114 Research is currently uncertain if placing a temporary stent during ureteroscopy leads to different outcomes than not placing a stent in terms of number of hospital visits for post operative problems short or long term pain need for narcotic pain medication risk of UTI need for a repeat procedure or narrowing of the ureter from scarring 115 More definitive ureteroscopic techniques for stone extraction rather than simply bypassing the obstruction include basket extraction and ultrasound ureterolithotripsy Laser lithotripsy is another technique which involves the use of a holmium yttrium aluminium garnet Ho YAG laser to fragment stones in the bladder ureters and kidneys 116 Ureteroscopic techniques are generally more effective than ESWL for treating stones located in the lower ureter with success rates of 93 100 using Ho YAG laser lithotripsy 84 Although ESWL has been traditionally preferred by many practitioners for treating stones located in the upper ureter more recent experience suggests ureteroscopic techniques offer distinct advantages in the treatment of upper ureteral stones Specifically the overall success rate is higher fewer repeat interventions and postoperative visits are needed and treatment costs are lower after ureteroscopic treatment when compared with ESWL These advantages are especially apparent with stones greater than 10 mm 0 4 in in diameter However because ureteroscopy of the upper ureter is much more challenging than ESWL many urologists still prefer to use ESWL as a first line treatment for stones of less than 10 mm and ureteroscopy for those greater than 10 mm in diameter 84 Ureteroscopy is the preferred treatment in pregnant and morbidly obese people as well as those with bleeding disorders 7 Epidemiology editCountry Earliest prevalence years 117 Latest prevalence years 117 United States 2 6 1964 1972 5 2 1988 1994 Italy 1 2 1983 1 7 1993 1994 Scotland 3 8 1977 3 5 1987 Spain 0 1 1977 10 0 1991 Turkey n a 14 8 1989 Country New cases per 100 000 year 117 Trend United States 116 2000 decreasing Germany 720 2000 increasing Japan 114 3 2005 increasing Spain 270 1984 decreasing Sweden 200 1969 increasing nbsp Urolithiasis deaths per million persons in 2012 0 0 1 1 2 2 3 3 4 20 Kidney stones affect all geographical cultural and racial groups The lifetime risk is about 10 15 in the developed world but can be as high as 20 25 in the Middle East The increased risk of dehydration in hot climates coupled with a diet 50 lower in calcium and 250 higher in oxalates compared to Western diets accounts for the higher net risk in the Middle East 118 In the Middle East uric acid stones are more common than calcium containing stones 25 The number of deaths due to kidney stones is estimated at 19 000 per year being fairly consistent between 1990 and 2010 119 In North America and Europe the annual number of new cases per year of kidney stones is roughly 0 5 In the United States the frequency in the population of urolithiasis has increased from 3 2 to 5 2 from the mid 1970s to the mid 1990s 21 In the United States about 9 of the population has had a kidney stone 2 The total cost for treating urolithiasis was US 2 billion in 2003 58 About 65 80 of those with kidney stones are men most stones in women are due to either metabolic defects such as cystinuria or infections in the case of struvite stones 75 120 19 Urinary tract calculi disorders are more common in men than in women Men most commonly experience their first episode between 30 and 40 years of age whereas for women the age at first presentation is somewhat later 75 The age of onset shows a bimodal distribution in women with episodes peaking at 35 and 55 years 58 Recurrence rates are estimated at 50 over a 10 year and 75 over 20 year period 21 with some people experiencing ten or more episodes over the course of a lifetime 75 A 2010 review concluded that rates of disease are increasing 117 History editSee also List of kidney stone formers The existence of kidney stones was first recorded thousands of years ago with various explanations given Joseph Glanville s Saducismus Triumphatus for example gives a detailed description of Abraham Mechelburg s voiding of small stones through his penis virga attributing the issue to witchcraft 121 In 1901 a stone discovered in the pelvis of an ancient Egyptian mummy was dated to 4 800 BC Medical texts from ancient Mesopotamia India China Persia Greece and Rome all mentioned calculous disease Part of the Hippocratic Oath suggests there were practicing surgeons in ancient Greece to whom physicians were to defer for lithotomies or the surgical removal of stones The Roman medical treatise De Medicina by Aulus Cornelius Celsus contained a description of lithotomy 122 and this work served as the basis for this procedure until the 18th century 123 Examples of people who had kidney stone disease include Napoleon I Epicurus Napoleon III Peter the Great Louis XIV George IV Oliver Cromwell Lyndon B Johnson Benjamin Franklin Michel de Montaigne Francis Bacon Isaac Newton Samuel Pepys William Harvey Herman Boerhaave and Antonio Scarpa 124 New techniques in lithotomy began to emerge starting in 1520 but the operation remained risky After Henry Jacob Bigelow popularized the technique of litholapaxy in 1878 125 the mortality rate dropped from about 24 to 2 4 However other treatment techniques continued to produce a high level of mortality especially among inexperienced urologists 123 124 In 1980 Dornier MedTech introduced extracorporeal shock wave lithotripsy for breaking up stones via acoustical pulses and this technique has since come into widespread use 106 Etymology edit The term renal calculus is from the Latin renes meaning kidneys and calculus meaning pebble Lithiasis stone formation in the kidneys is called nephrolithiasis ˌ n ɛ f r oʊ l ɪ ˈ 8 aɪ e s ɪ s from nephro meaning kidney lith meaning stone and iasis meaning disorder A distinction between nephrolithiasis and urolithiasis can be made because not all urinary stones uroliths form in the kidney they can also form in the bladder But the distinction is often clinically irrelevant with similar disease process and treatment either way and the words are thus often used loosely as synonyms Children editAlthough kidney stones do not often occur in children the incidence is increasing 126 These stones are in the kidney in two thirds of reported cases and in the ureter in the remaining cases Older children are at greater risk independent of whether or not they are male or female 127 As with adults most pediatric kidney stones are predominantly composed of calcium oxalate struvite and calcium phosphate stones are less common Calcium oxalate stones in children are associated with high amounts of calcium oxalate and magnesium in acidic urine 128 Treatment of kidney stones in children is similar to treatments for adults including shock wave lithotripsy medication and treatment using scope through the bladder kidney or skin 129 Of these treatments research is uncertain if shock waves are more effective than medication or a scope through the bladder but it is likely less successful than a scope through skin into the kidney 129 When going in with a scope through the kidney a regular and a mini sized scope likely have similar success rates of stone removal Alpha blockers a type of medication may increase the successful removal of kidney stones when compared with a placebo and without ibuprofen 129 Research editMetabolic syndrome and its associated diseases of obesity and diabetes as general risk factors for kidney stone disease are under research to determine if urinary excretion of calcium oxalate and urate are higher than in people with normal weight or underweight and if diet and physical activity have roles 130 131 Dietary fluid intake and lifestyle factors remain major topics for research on prevention of kidney stones as of 2017 132 Gut microbiota edit The gut microbiota has been explored as a contributing factor for stone disease indicating that some bacteria may be different in people forming kidney stones 133 One bacterium Oxalobacter formigenes is potentially beneficial for mitigating calcium oxalate stones because of its ability to metabolize oxalate as its sole carbon source 134 but 2018 research suggests that it is instead part of a network of oxalate degrading bacteria 135 Additionally one study found that oral antibiotic use which alters the gut microbiota 136 can increase the odds of a person developing a kidney stone 137 In animals editAmong ruminants uroliths more commonly cause problems in males than in females the sigmoid flexure of the ruminant male urinary tract is more likely to obstruct passage Early castrated males are at greater risk because of lesser urethral diameter 138 Low Ca P intake ratio is conducive to phosphatic e g struvite urolith formation 138 Incidence among wether lambs can be minimized by maintaining a dietary Ca P intake ratio of 2 1 138 139 Alkaline higher pH favors formation of carbonate and phosphate calculi For domestic ruminants dietary cation anion balance is sometimes adjusted to assure a slightly acidic urine pH for prevention of calculus formation 138 Differing generalizations regarding effects of pH on formation of silicate uroliths may be found 138 140 In this connection it may be noted that under some circumstances calcium carbonate accompanies silica in siliceous uroliths 141 Pelleted feeds may be conducive to formation of phosphate uroliths because of increased urinary phosphorus excretion This is attributable to lower saliva production where pelleted rations containing finely ground constituents are fed With less blood phosphate partitioned into saliva more tends to be excreted in urine 142 Most saliva phosphate is fecally excreted 143 Oxalate uroliths can occur in ruminants although such problems from oxalate ingestion may be relatively uncommon Ruminant urolithiasis associated with oxalate ingestion has been reported 144 However no renal tubular damage or visible deposition of calcium oxalate crystals in kidneys was found in yearling wether sheep fed diets containing soluble oxalate at 6 5 percent of dietary dry matter for about 100 days 145 Conditions limiting water intake can result in stone formation 146 Various surgical interventions e g amputation of the urethral process at its base near the glans penis in male ruminants perineal urethrostomy or tube cystostomy may be considered for relief of obstructive urolithiasis 146 See also editNephrocalcinosis Kidney disease Kidney stone formation in spaceReferences edit a b Schulsinger DA 2014 Kidney Stone Disease Say NO to Stones Springer p 27 ISBN 978 3 319 12105 5 Archived from the original on 8 September 2017 a b c d e f g h i j k l m n o p q r s Kidney Stones in Adults February 2013 Archived from the original on 11 May 2015 Retrieved 22 May 2015 Knoll T Pearle MS 2012 Clinical Management of Urolithiasis Springer Science amp Business Media p 21 ISBN 978 3 642 28732 9 Archived from the original on 8 September 2017 a b c d Qaseem A Dallas P Forciea MA Starkey M Denberg TD November 2014 Dietary and pharmacologic management to prevent recurrent nephrolithiasis in adults a clinical practice guideline from the American College of Physicians Annals of Internal Medicine 161 9 659 67 doi 10 7326 M13 2908 PMID 25364887 a b Vos T Allen C Arora M Barber RM Bhutta ZA Brown A Carter A Casey DC Charlson FJ Chen AZ Coggeshall M Cornaby L Dandona L Dicker DJ Dilegge T Erskine HE Ferrari AJ Fitzmaurice C Fleming T Forouzanfar MH Fullman N Gething PW Goldberg EM Graetz N Haagsma JA Hay SI Johnson CO Kassebaum NJ Kawashima T Kemmer L et al GBD 2015 Disease and Injury Incidence and Prevalence Collaborators October 2016 Global regional and national incidence prevalence and years lived with disability for 310 diseases and injuries 1990 2015 a systematic analysis for the Global Burden of Disease Study 2015 Lancet 388 10053 1545 1602 doi 10 1016 S0140 6736 16 31678 6 PMC 5055577 PMID 27733282 a b Wang H Naghavi M Allen C Barber RM Bhutta ZA Carter A Casey DC Charlson FJ Chen AZ Coates MM Coggeshall M Dandona L Dicker DJ Erskine HE Ferrari AJ Fitzmaurice C Foreman K Forouzanfar MH Fraser MS Fullman N Gething PW Goldberg EM Graetz N Haagsma JA Hay SI Huynh C Johnson CO Kassebaum NJ Kinfu Y Kulikoff XR et al GBD 2015 Disease and Injury Incidence and Prevalence Collaborators October 2016 Global regional and national life expectancy all cause mortality and cause specific mortality for 249 causes of death 1980 2015 a systematic analysis for the Global Burden of Disease Study 2015 Lancet 388 10053 1459 1544 doi 10 1016 s0140 6736 16 31012 1 PMC 5388903 PMID 27733281 a b c d e f g h i j Miller NL Lingeman JE March 2007 Management of kidney stones BMJ 334 7591 468 72 doi 10 1136 bmj 39113 480185 80 PMC 1808123 PMID 17332586 a b c d Morgan MS Pearle MS March 2016 Medical management of renal stones BMJ 352 i52 doi 10 1136 bmj i52 PMID 26977089 S2CID 28313474 a b Afshar K Jafari S Marks AJ Eftekhari A MacNeily AE June 2015 Nonsteroidal anti inflammatory drugs NSAIDs and non opioids for acute renal colic The Cochrane Database of Systematic Reviews 2015 6 CD006027 doi 10 1002 14651858 CD006027 pub2 PMC 10981792 PMID 26120804 Wang RC Smith Bindman R Whitaker E Neilson J Allen IE Stoller ML Fahimi J March 2017 Effect of Tamsulosin on Stone Passage for Ureteral Stones A Systematic Review and Meta analysis Annals of Emergency Medicine 69 3 353 361 e3 doi 10 1016 j annemergmed 2016 06 044 PMID 27616037 a b Abufaraj M Xu T Cao C Waldhoer T Seitz C D andrea D Siyam A Tarawneh R Fajkovic H Schernhammer E Yang L Shariat SF November 2021 Prevalence and Trends in Kidney Stone Among Adults in the USA Analyses of National Health and Nutrition Examination Survey 2007 2018 Data European Urology Focus 7 6 1468 1475 doi 10 1016 j euf 2020 08 011 PMID 32900675 S2CID 221572651 Stamatelou KK Francis ME Jones CA Nyberg LM Curhan GC May 2003 Time trends in reported prevalence of kidney stones in the United States 1976 199411 See Editorial by Goldfarb p 1951 Kidney International 63 5 1817 1823 doi 10 1046 j 1523 1755 2003 00917 x PMID 12675858 Stamatelou K Goldfarb DS January 2023 Epidemiology of Kidney Stones Healthcare 11 3 424 doi 10 3390 healthcare11030424 ISSN 2227 9032 PMC 9914194 PMID 36766999 nbsp This article incorporates text from this source which is available under the CC BY 4 0 license a b c d e f g Preminger GM 2007 Chapter 148 Stones in the Urinary Tract In Cutler RE ed The Merck Manual of Medical Information Home Edition 3rd ed Whitehouse Station New Jersey Merck Sharp and Dohme Corporation Archived from the original on 8 December 2014 Retrieved 7 August 2011 Nephrolithiasis Overview at eMedicine Background a b c Pearle MS Calhoun EA Curhan GC 2007 Ch 8 Urolithiasis PDF In Litwin MS Saigal CS eds Urologic Diseases in America NIH Publication No 07 5512 Bethesda Maryland National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health United States Public Health Service United States Department of Health and Human Services pp 283 319 Archived PDF from the original on 18 October 2011 a b Cavendish M 2008 Kidney disorders Diseases and Disorders Vol 2 1st ed Tarrytown New York Marshall Cavendish Corporation pp 490 3 ISBN 978 0 7614 7772 3 Archived from the original on 14 April 2021 Retrieved 6 November 2020 a b Curhan GC Willett WC Rimm EB Spiegelman D Stampfer MJ February 1996 Prospective study of beverage use and the risk of kidney stones American Journal of Epidemiology 143 3 240 7 doi 10 1093 oxfordjournals aje a008734 PMID 8561157 a b c d Lewis SM 2017 Medical surgical nursing assessment and management of clinical problems Elsevier ISBN 978 0 323 32852 4 OCLC 944472408 Knight J Assimos DG Easter L Holmes RP November 2010 Metabolism of fructose to oxalate and glycolate Hormone and Metabolic Research 42 12 868 73 doi 10 1055 s 0030 1265145 PMC 3139422 PMID 20842614 a b c d Moe OW January 2006 Kidney stones pathophysiology and medical management PDF Lancet 367 9507 333 44 doi 10 1016 S0140 6736 06 68071 9 PMID 16443041 S2CID 26581831 Archived PDF from the original on 15 August 2011 Thakker RV March 2000 Pathogenesis of Dent s disease and related syndromes of X linked nephrolithiasis PDF Kidney International 57 3 787 93 doi 10 1046 j 1523 1755 2000 00916 x PMID 10720930 Archived PDF from the original on 5 November 2012 a b National Endocrine and Metabolic Diseases Information Service 2006 Hyperparathyroidism NIH Publication No 6 3425 Information about Endocrine and Metabolic Diseases A Z list of Topics and Titles Bethesda Maryland National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Public Health Service US Department of Health and Human Services Archived from the original on 24 May 2011 Retrieved 27 July 2011 a b Hoppe B Langman CB October 2003 A United States survey on diagnosis treatment and outcome of primary hyperoxaluria Pediatric Nephrology 18 10 986 91 doi 10 1007 s00467 003 1234 x PMID 12920626 S2CID 23503869 a b c d e Reilly RF Ch 13 Nephrolithiasis In Reilly amp Perazella 2005 pp 192 207 National Kidney and Urologic Diseases Information Clearinghouse 2008 Medullary Sponge Kidney NIH Publication No 08 6235 Kidney amp Urologic Diseases A Z list of Topics and Titles Bethesda Maryland National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Public Health Service US Department of Health and Human Services Archived from the original on 7 August 2011 Retrieved 27 July 2011 National Digestive Diseases Information Clearinghouse 2006 Crohn s Disease NIH Publication No 06 3410 Digestive Diseases A Z List of Topics and Titles Bethesda Maryland National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health United States Public Health Service United States Department of Health and Human Services Archived from the original on 9 June 2014 Retrieved 27 July 2011 Farmer RG Mir Madjlessi SH Kiser WS 1974 Urinary excretion of oxalate calcium magnesium and uric acid in inflammatory bowel disease Cleveland Clinic Quarterly 41 3 109 17 doi 10 3949 ccjm 41 3 109 PMID 4416806 Archived from the original on 20 March 2020 Retrieved 1 November 2013 a b c Tolerable upper intake levels Calcium and vitamin D In Committee to Review Dietary Reference Intakes for Vitamin D and Calcium 2011 pp 403 56 a b c d e f g h Johri N Cooper B Robertson W Choong S Rickards D Unwin R 2010 An update and practical guide to renal stone management Nephron Clinical Practice 116 3 c159 71 doi 10 1159 000317196 PMID 20606476 Archived from the original on 31 January 2021 Retrieved 18 May 2019 Summary In Committee to Review Dietary Reference Intakes for Vitamin D and Calcium 2011 pp 1 14 a b c Parmar MS June 2004 Kidney stones BMJ 328 7453 1420 4 doi 10 1136 bmj 328 7453 1420 PMC 421787 PMID 15191979 Liebman M Al Wahsh IA May 2011 Probiotics and other key determinants of dietary oxalate absorption PDF Advances in Nutrition 2 3 254 60 doi 10 3945 an 111 000414 PMC 3090165 PMID 22332057 Archived PDF from the original on 16 January 2016 Committee on Fluoride in Drinking Water of the National Academy of Sciences 2006 Chapter 9 Effects on the Renal System Fluoride in Drinking Water A Scientific Review of EPA s Standards Washington DC The National Academies Press pp 236 48 ISBN 978 0 309 65799 0 Archived from the original on 30 July 2011 Ferraro PM Mandel EI Curhan GC Gambaro G Taylor EN October 2016 Dietary Protein and Potassium Diet Dependent Net Acid Load and Risk of Incident Kidney Stones Clinical Journal of the American Society of Nephrology 11 10 1834 1844 doi 10 2215 CJN 01520216 PMC 5053786 PMID 27445166 a b Riley JM Kim H Averch TD Kim HJ December 2013 Effect of magnesium on calcium and oxalate ion binding Journal of Endourology 27 12 1487 92 doi 10 1089 end 2013 0173 PMC 3883082 PMID 24127630 a b Negri AL Spivacow FR Del Valle EE 2013 Diet in the treatment of renal lithiasis Pathophysiological basis Medicina 73 3 267 71 PMID 23732207 Goodwin JS Tangum MR November 1998 Battling quackery attitudes about micronutrient supplements in American academic medicine Archives of Internal Medicine 158 20 2187 91 doi 10 1001 archinte 158 20 2187 PMID 9818798 Traxer O Pearle MS Gattegno B Thibault P December 2003 Vitamin C and stone risk Review of the literature Progres en Urologie 13 6 1290 4 PMID 15000301 Ferraro PM Curhan GC Gambaro G Taylor EN March 2016 Total Dietary and Supplemental Vitamin C Intake and Risk of Incident Kidney Stones American Journal of Kidney Diseases 67 3 400 7 doi 10 1053 j ajkd 2015 09 005 PMC 4769668 PMID 26463139 Perazella MA Ch 14 Urinalysis In Reilly amp Perazella 2005 pp 209 26 a b c d e f Knudsen BE Beiko DT Denstedt JD Ch 16 Uric Acid Urolithiasis In Stoller amp Meng 2007 pp 299 308 Nephrolithiasis Overview at eMedicine Pathophysiology Robertson WG Peacock M Nordin BE July 1969 Calcium crystalluria in recurrent renal stone formers Lancet 2 7610 21 24 doi 10 1016 S0140 6736 69 92598 7 PMID 4182793 Elliot JS Rabinowitz IN March 1980 Calcium oxalate crystalluria crystal size in urine The Journal of Urology 123 3 324 327 doi 10 1016 S0022 5347 17 55918 2 PMID 7359628 Randall A June 1937 The Origin and Growth of Renal Calculi Annals of Surgery 105 6 1009 1027 doi 10 1097 00000658 193706000 00014 PMC 1390483 PMID 17856988 Ratkalkar VN Kleinman JG December 2011 Mechanisms of Stone Formation Clinical Reviews in Bone and Mineral Metabolism 9 3 4 187 197 doi 10 1007 s12018 011 9104 8 PMC 3252394 PMID 22229020 Khan SR September 2014 Reactive oxygen species inflammation and calcium oxalate nephrolithiasis Translational Andrology and Urology 3 3 256 276 doi 10 3978 j issn 2223 4683 2014 06 04 PMC 4220551 PMID 25383321 Jones BD Mobley HL August 1988 Proteus mirabilis urease genetic organization regulation and expression of structural genes Journal of Bacteriology 170 8 3342 3349 doi 10 1128 jb 170 8 3342 3349 1988 PMC 211300 PMID 2841283 Chmiel JA Stuivenberg GA Alathel A Gorla J Grohe B Razvi H Burton JP Bjazevic J December 2021 High Throughput in vitro Gel Based Plate Assay to Screen for Calcium Oxalate Stone Inhibitors Urologia Internationalis 106 6 616 622 doi 10 1159 000519842 PMID 34883484 S2CID 245012979 Kanlaya R Naruepantawart O Thongboonkerd V 5 November 2019 Flagellum Is Responsible for Promoting Effects of Viable Escherichia coli on Calcium Oxalate Crystallization Crystal Growth and Crystal Aggregation Frontiers in Microbiology 10 2507 doi 10 3389 fmicb 2019 02507 PMC 6848068 PMID 31749785 a b c Coe FL Evan A Worcester E October 2005 Kidney stone disease The Journal of Clinical Investigation 115 10 2598 608 doi 10 1172 JCI26662 PMC 1236703 PMID 16200192 del Valle EE Spivacow FR Negri AL 2013 Citrate and renal stones Medicina 73 4 363 8 PMID 23924538 Educate Your Patients about Kidney Stones PDF kidney org Archived PDF from the original on 26 October 2020 Caudarella R Vescini F September 2009 Urinary citrate and renal stone disease the preventive role of alkali citrate treatment Archivio Italiano di Urologia Andrologia 81 3 182 7 PMID 19911682 a b c d e Anoia EJ Paik ML Resnick MI 2009 Ch 7 Anatrophic Nephrolithomy In Graham SD Keane TE eds Glenn s Urologic Surgery 7th ed Philadelphia Lippincott Williams amp Wilkins pp 45 50 ISBN 978 0 7817 9141 0 Archived from the original on 14 April 2021 Retrieved 6 November 2020 Weaver SH Jenkins P 2002 Ch 14 Renal and Urological Care Illustrated Manual of Nursing Practice 3rd ed Lippincott Williams amp Wilkins ISBN 978 1 58255 082 4 a b c d e f Pietrow PK Karellas ME July 2006 Medical management of common urinary calculi PDF American Family Physician 74 1 86 94 PMID 16848382 Archived PDF from the original on 23 November 2011 Brisbane W Bailey MR Sorensen MD November 2016 An overview of kidney stone imaging techniques Nature Reviews Urology 13 11 654 662 doi 10 1038 nrurol 2016 154 ISSN 1759 4812 PMC 5443345 PMID 27578040 a b c Smith RC Varanelli M July 2000 Diagnosis and management of acute ureterolithiasis CT is truth AJR American Journal of Roentgenology 175 1 3 6 doi 10 2214 ajr 175 1 1750003 PMID 10882237 S2CID 73387308 Bushinsky D Coe FL Moe OW 2007 Ch 37 Nephrolithiasis In Brenner BM ed Brenner and Rector s The Kidney Vol 1 8th ed Philadelphia WB Saunders pp 1299 349 ISBN 978 1 4160 3105 5 Archived from the original on 8 October 2011 Smith RC Levine J Rosenfeld AT September 1999 Helical CT of urinary tract stones Epidemiology origin pathophysiology diagnosis and management Radiologic Clinics of North America 37 5 911 52 v doi 10 1016 S0033 8389 05 70138 X PMID 10494278 American College of Emergency Physicians 27 October 2014 Ten Things Physicians and Patients Should Question Choosing Wisely Archived from the original on 7 March 2014 Retrieved 14 January 2015 American Urological Association Choosing Wisely www choosingwisely org Archived from the original on 23 February 2017 Retrieved 28 May 2017 a b c Fang LS 2009 Chapter 135 Approach to the Paient with Nephrolithiasis In Goroll AH Mulley AG eds Primary care medicine office evaluation and management of the adult patient 6th ed Philadelphia Lippincott Williams amp Wilkins pp 962 7 ISBN 978 0 7817 7513 7 Archived from the original on 21 March 2021 Retrieved 6 November 2020 a b Semins MJ Matlaga BR September 2013 Management of urolithiasis in pregnancy International Journal of Women s Health 5 599 604 doi 10 2147 ijwh s51416 PMC 3792830 PMID 24109196 Smith Bindman R Aubin C Bailitz J Bengiamin RN Camargo CA Corbo J Dean AJ Goldstein RB Griffey RT Jay GD Kang TL Kriesel DR Ma OJ Mallin M Manson W Melnikow J Miglioretti DL Miller SK Mills LD Miner JR Moghadassi M Noble VE Press GM Stoller ML Valencia VE Wang J Wang RC Cummings SR September 2014 Ultrasonography versus computed tomography for suspected nephrolithiasis PDF The New England Journal of Medicine 371 12 1100 10 doi 10 1056 NEJMoa1404446 PMID 25229916 S2CID 4511678 Archived PDF from the original on 14 March 2020 Retrieved 25 September 2019 National Kidney and Urologic Diseases Information Clearinghouse 2007 Kidney Stones in Adults NIH Publication No 08 2495 Kidney amp Urologic Diseases A Z list of Topics and Titles Bethesda Maryland National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Public Health Service US Department of Health and Human Services Archived from the original on 26 July 2011 Retrieved 27 July 2011 a b Frassetto L Kohlstadt I 2011 Treatment and prevention of kidney stones an update Am Fam Physician 84 11 1234 42 PMID 22150656 Including cystine stone incidence of 1 Becker KL 2001 Principles and practice of endocrinology and metabolism 3 ed Philadelphia Pa u a Lippincott Williams amp Wilkins p 684 ISBN 978 0 7817 1750 2 Archived from the original on 8 September 2017 Cystine stones UpToDate Archived from the original on 26 February 2014 Retrieved 20 February 2014 Bailey amp Love s 25th 1296 National Endocrine and Metabolic Diseases Information Service 2008 Renal Tubular Acidosis NIH Publication No 09 4696 Kidney amp Urologic Diseases A Z list of Topics and Titles Bethesda Maryland National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Public Health Service US Department of Health and Human Services Archived from the original on 28 July 2011 Retrieved 27 July 2011 a b c d De Mais D 2009 ASCP Quick Compendium of Clinical Pathology 2nd ed Chicago ASCP Press a b c d e Weiss M Liapis H Tomaszewski JE Arend LJ 2007 Chapter 22 Pyelonephritis and Other Infections Reflux Nephropathy Hydronephrosis and Nephrolithiasis In Jennette JC Olson JL Schwartz MM Silva FG eds Heptinstall s Pathology of the Kidney Vol 2 6th ed Philadelphia Lippincott Williams amp Wilkins pp 991 1082 ISBN 978 0 7817 4750 9 Archived from the original on 20 March 2021 Retrieved 6 November 2020 Halabe A Sperling O 1994 Uric acid nephrolithiasis Mineral and Electrolyte Metabolism 20 6 424 31 PMID 7783706 Kamatani N December 1996 Adenine phosphoribosyltransferase APRT deficiency Nihon Rinsho Japanese Journal of Clinical Medicine in Japanese 54 12 3321 7 PMID 8976113 Rosenberg LE Durant JL Elsas LJ June 1968 Familial iminoglycinuria An inborn error of renal tubular transport The New England Journal of Medicine 278 26 1407 13 doi 10 1056 NEJM196806272782601 PMID 5652624 Coskun T Ozalp I Tokatli A 1993 Iminoglycinuria a benign type of inherited aminoaciduria The Turkish Journal of Pediatrics 35 2 121 5 PMID 7504361 Patient Information about Crixivan for HIV Human Immunodeficiency Virus Infection PDF Crixivan indinavir sulfate Capsules Whitehouse Station New Jersey Merck Sharp amp Dohme Corporation 2010 Archived PDF from the original on 15 August 2011 Retrieved 27 July 2011 Schlossberg D Samuel R 2011 Sulfadiazine Antibiotic Manual A Guide to Commonly Used Antimicrobials 1st ed Shelton Connecticut People s Medical Publishing House pp 411 12 ISBN 978 1 60795 084 4 Archived from the original on 20 March 2021 Retrieved 25 August 2020 Carr MC Prien EL Babayan RK December 1990 Triamterene nephrolithiasis renewed attention is warranted The Journal of Urology 144 6 1339 40 doi 10 1016 S0022 5347 17 39734 3 PMID 2231920 McNutt WF 1893 Section IV Diseases of the Bladder Chapter VII Vesical Calculi Cysto lithiasis Diseases of the Kidneys and Bladder A Text Book for Students of Medicine Philadelphia J B Lippincott Company pp 185 6 Archived from the original on 14 April 2021 Retrieved 6 November 2020 a b c d e Gettman MT Segura JW March 2005 Management of ureteric stones issues and controversies BJU International 95 Suppl 2 85 93 doi 10 1111 j 1464 410X 2005 05206 x PMID 15720341 S2CID 36265416 Segura JW February 1997 Staghorn calculi The Urologic Clinics of North America 24 1 71 80 doi 10 1016 S0094 0143 05 70355 4 PMID 9048853 a b Fink HA Wilt TJ Eidman KE Garimella PS MacDonald R Rutks IR Brasure M Kane RL Ouellette J Monga M April 2013 Medical management to prevent recurrent nephrolithiasis in adults a systematic review for an American College of Physicians Clinical Guideline Annals of Internal Medicine 158 7 535 43 doi 10 7326 0003 4819 158 7 201304020 00005 PMID 23546565 a b Qaseem A Dallas P Forciea MA Starkey M Denberg TD November 2014 Dietary and pharmacologic management to prevent recurrent nephrolithiasis in adults a clinical practice guideline from the American College of Physicians Annals of Internal Medicine 161 9 659 67 doi 10 7326 m13 2908 PMID 25364887 Goldfarb DS Coe FL November 1999 Prevention of recurrent nephrolithiasis American Family Physician 60 8 2269 76 PMID 10593318 Archived from the original on 22 August 2005 a b Finkielstein VA Goldfarb DS May 2006 Strategies for preventing calcium oxalate stones CMAJ 174 10 1407 9 doi 10 1503 cmaj 051517 PMC 1455427 PMID 16682705 Archived from the original on 15 October 2008 a b Fink HA Wilt TJ Eidman KE Garimella PS MacDonald R Rutks IR Brasure M Kane RL Monga M July 2012 Recurrent Nephrolithiasis in Adults Comparative Effectiveness of Preventive Medical Strategies Comparative Effectiveness Reviews 61 Rockvill MD Agency for Healthcare Research and Quality PMID 22896859 Ferraro PM Taylor EN Gambaro G Curhan GC August 2013 Soda and other beverages and the risk of kidney stones Clinical Journal of the American Society of Nephrology 8 8 1389 95 doi 10 2215 CJN 11661112 PMC 3731916 PMID 23676355 What are kidney stones kidney org Archived from the original on 14 May 2013 Retrieved 19 August 2013 Taylor EN Curhan GC September 2006 Diet and fluid prescription in stone disease Kidney International 70 5 835 9 doi 10 1038 sj ki 5001656 PMID 16837923 Gul Z Monga M December 2014 Medical and dietary therapy for kidney stone prevention Korean Journal of Urology 55 12 775 9 doi 10 4111 kju 2014 55 12 775 PMC 4265710 PMID 25512810 Citric Acid and Kidney Stones PDF uwhealth org Archived PDF from the original on 5 July 2010 Heaney RP March 2006 Nutrition and chronic disease Mayo Clinic Proceedings 81 3 297 9 doi 10 4065 81 3 297 PMID 16529131 a b Tiselius HG May 2003 Epidemiology and medical management of stone disease BJU International 91 8 758 67 doi 10 1046 j 1464 410X 2003 04208 x PMID 12709088 S2CID 28256459 a b Taylor EN Stampfer MJ Curhan GC December 2004 Dietary factors and the risk of incident kidney stones in men new insights after 14 years of follow up PDF Journal of the American Society of Nephrology 15 12 3225 32 doi 10 1097 01 ASN 0000146012 44570 20 PMID 15579526 Archived PDF from the original on 21 September 2017 Retrieved 3 June 2011 Cicerello E Merlo F Maccatrozzo L September 2010 Urinary alkalization for the treatment of uric acid nephrolithiasis Archivio Italiano di Urologia Andrologia 82 3 145 8 PMID 21121431 Effect of addition of calcium hydroxide to foods rich in oxalic acid on calcium and oxalic acid metabolism Request PDF Archived from the original on 7 November 2021 Retrieved 6 March 2021 Cameron JS Simmonds HA June 1987 Use and abuse of allopurinol British Medical Journal 294 6586 1504 5 doi 10 1136 bmj 294 6586 1504 PMC 1246665 PMID 3607420 Macaluso JN November 1996 Management of stone disease bearing the burden The Journal of Urology 156 5 1579 80 doi 10 1016 S0022 5347 01 65452 1 PMID 8863542 Pathan SA Mitra B Cameron PA April 2018 A Systematic Review and Meta analysis Comparing the Efficacy of Nonsteroidal Anti inflammatory Drugs Opioids and Paracetamol in the Treatment of Acute Renal Colic European Urology 73 4 583 595 doi 10 1016 j eururo 2017 11 001 PMID 29174580 a b c Seitz C Liatsikos E Porpiglia F Tiselius HG Zwergel U September 2009 Medical therapy to facilitate the passage of stones what is the evidence European Urology 56 3 455 71 doi 10 1016 j eururo 2009 06 012 PMID 19560860 a b c d e Campschroer T Zhu X Vernooij RW Lock MT April 2018 Alpha blockers as medical expulsive therapy for ureteral stones The Cochrane Database of Systematic Reviews 2018 4 CD008509 doi 10 1002 14651858 CD008509 pub3 PMC 6494465 PMID 29620795 a b c d e f g h i Shock Wave Lithotripsy Task Force 2009 Current Perspective on Adverse Effects in Shock Wave Lithotripsy PDF Clinical Guidelines Linthicum Maryland American Urological Association Archived from the original PDF on 18 July 2013 Retrieved 13 October 2015 Lingeman JE Matlaga BR Evan AP 2007 Surgical Management of Urinary Lithiasis In Wein AJ Kavoussi LR Novick AC Partin AW Peters CA eds Campbell Walsh Urology Philadelphia W B Saunders pp 1431 1507 Preminger GM Tiselius HG Assimos DG Alken P Buck C Gallucci M Knoll T Lingeman JE Nakada SY Pearle MS Sarica K Turk C Wolf JS December 2007 2007 guideline for the management of ureteral calculi The Journal of Urology 178 6 2418 34 doi 10 1016 j juro 2007 09 107 PMID 17993340 a b Evan AP McAteer JA 1996 Ch 28 Q effects of Shock Wave Lithotripsy In Coe FL Favus MJ Pak CY Parks JH Preminger GM eds Kidney Stones Medical and Surgical Management Philadelphia Lippincott Raven pp 549 60 ISBN 978 0 7817 0263 8 a b c Evan AP Willis LR 2007 Ch 41 Extracorporeal Shock Wave Lithotripsy Complications In Smith AD Badlani GH Bagley DH Clayman RV Docimo SG eds Smith s Textbook on Endourology Hamilton Ontario Canada B C Decker Inc pp 353 65 a b c Oestreich MC Vernooij RW Sathianathen NJ Hwang EC Kuntz GM Koziarz A Scales CD Dahm P et al Cochrane Urology Group November 2020 Alpha blockers after shock wave lithotripsy for renal or ureteral stones in adults The Cochrane Database of Systematic Reviews 2020 11 CD013393 doi 10 1002 14651858 CD013393 pub2 PMC 8092672 PMID 33179245 Young JG Keeley FX Ch 38 Indications for Surgical Removal Including Asymptomatic Stones in Rao Preminger amp Kavanagh 2011 pp 441 454 Wynberg JB Borin JF Vicena JZ Hannosh V Salmon SA October 2012 Flexible ureteroscopy directed retrograde nephrostomy for percutaneous nephrolithotomy description of a technique Journal of Endourology 26 10 1268 74 doi 10 1089 end 2012 0160 PMID 22563900 Lam JS Gupta M Ch 25 Ureteral Stents In Stoller amp Meng 2007 pp 465 83 Ordonez M Hwang EC Borofsky M Bakker CJ Gandhi S Dahm P et al Cochrane Urology Group February 2019 Ureteral stent versus no ureteral stent for ureteroscopy in the management of renal and ureteral calculi The Cochrane Database of Systematic Reviews 2019 2 CD012703 doi 10 1002 14651858 CD012703 pub2 PMC 6365118 PMID 30726554 Marks AJ Qiu J Milner TE Chan KF Teichman JM 6 January 2011 Ch 26 Laser Lithotripsy Physics Springer ISBN 978 1 84800 362 0 archived from the original on 20 February 2021 retrieved 6 November 2020 in Rao Preminger amp Kavanagh 2011 pp 301 310 a b c d Romero V Akpinar H Assimos DG 2010 Kidney stones a global picture of prevalence incidence and associated risk factors Reviews in Urology 12 2 3 e86 96 PMC 2931286 PMID 20811557 Lieske JC Segura JW 2004 Ch 7 Evaluation and Medical Management of Kidney Stones In Potts JM ed Essential Urology A Guide to Clinical Practice 1st ed Totowa New Jersey Humana Press pp 117 52 ISBN 978 1 58829 109 7 Lozano R Naghavi M Foreman K Lim S Shibuya K Aboyans V Abraham J Adair T Aggarwal R Ahn SY Alvarado M Anderson HR Anderson LM Andrews KG Atkinson C Baddour LM Barker Collo S Bartels DH Bell ML Benjamin EJ Bennett D Bhalla K Bikbov B Bin Abdulhak A Birbeck G Blyth F Bolliger I Boufous S Bucello C Burch M Burney P Carapetis J Chen H Chou D Chugh SS Coffeng LE Colan SD Colquhoun S Colson KE Condon J Connor MD Cooper LT Corriere M Cortinovis M de Vaccaro KC Couser W Cowie BC Criqui MH Cross M Dabhadkar KC Dahodwala N De Leo D Degenhardt L Delossantos A Denenberg J Des Jarlais DC Dharmaratne SD Dorsey ER Driscoll T Duber H Ebel B Erwin PJ Espindola P Ezzati M Feigin V Flaxman AD Forouzanfar MH Fowkes FG Franklin R Fransen M Freeman MK Gabriel SE Gakidou E Gaspari F Gillum RF Gonzalez Medina D Halasa YA Haring D Harrison JE Havmoeller R Hay RJ Hoen B Hotez PJ Hoy D Jacobsen KH James SL Jasrasaria R Jayaraman S Johns N Karthikeyan G Kassebaum N Keren A Khoo JP Knowlton LM Kobusingye O Koranteng A Krishnamurthi R Lipnick M Lipshultz SE Ohno SL Mabweijano J MacIntyre MF Mallinger L March L Marks GB Marks R Matsumori A Matzopoulos R Mayosi BM McAnulty JH McDermott MM McGrath J Mensah GA Merriman TR Michaud C Miller M Miller TR Mock C Mocumbi AO Mokdad AA Moran A Mulholland K Nair MN Naldi L Narayan KM Nasseri K Norman P O Donnell M Omer SB Ortblad K Osborne R Ozgediz D Pahari B Pandian JD Rivero AP Padilla RP Perez Ruiz F Perico N Phillips D Pierce K Pope CA Porrini E Pourmalek F Raju M Ranganathan D Rehm JT Rein DB Remuzzi G Rivara FP Roberts T De Leon FR Rosenfeld LC Rushton L Sacco RL Salomon JA Sampson U Sanman E Schwebel DC Segui Gomez M Shepard DS Singh D Singleton J Sliwa K Smith E Steer A Taylor JA Thomas B Tleyjeh IM Towbin JA Truelsen T Undurraga EA Venketasubramanian N Vijayakumar L Vos T Wagner GR Wang M Wang W Watt K Weinstock MA Weintraub R Wilkinson JD Woolf AD Wulf S Yeh PH Yip P Zabetian A Zheng ZJ Lopez AD Murray CJ AlMazroa MA Memish ZA December 2012 Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010 a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 9859 2095 128 doi 10 1016 S0140 6736 12 61728 0 hdl 10536 DRO DU 30050819 PMC 10790329 PMID 23245604 S2CID 1541253 Archived from the original on 19 May 2020 Windus D 2008 The Washington manual nephrology subspecialty consult 2nd ed Philadelphia Wolters Kluwer Health Lippincott Williams amp Wilkins Health p 235 ISBN 978 0 7817 9149 6 Archived from the original on 9 September 2016 Glanvill J Saducismus triumphatus or Full and plain evidence concerning witches and apparitions in two parts the first treating of their possibility the second of their real existence ISBN 1 171 33286 6 OCLC 943229347 Celsus AC 1831 Book VII Chapter XXVI Of the operation necessary in a suppression of urine and lithotomy In Collier GF ed A translation of the eight books of Aul Corn Celsus on medicine 2nd ed London Simpkin and Marshall pp 306 14 Archived from the original on 8 July 2014 a b Shah J Whitfield HN May 2002 Urolithiasis through the ages BJU International 89 8 801 10 doi 10 1046 j 1464 410X 2002 02769 x PMID 11972501 S2CID 44311421 a b Ellis H 1969 A History of Bladder Stone Oxford England Blackwell Scientific Publications ISBN 978 0 632 06140 2 Bigelow HJ 1878 Litholapaxy or rapid lithotrity with evacuation Boston A Williams and Company p 29 Archived from the original on 14 April 2021 Retrieved 25 August 2020 Dwyer ME Krambeck AE Bergstralh EJ Milliner DS Lieske JC Rule AD July 2012 Temporal trends in incidence of kidney stones among children a 25 year population based study The Journal of Urology 188 1 247 52 doi 10 1016 j juro 2012 03 021 PMC 3482509 PMID 22595060 Diet and Definition of Kidney Stones Renal Calculi Archived from the original on 17 November 2007 Retrieved 11 October 2013 Kirejczyk JK Porowski T Filonowicz R Kazberuk A Stefanowicz M Wasilewska A Debek W February 2014 An association between kidney stone composition and urinary metabolic disturbances in children Journal of Pediatric Urology 10 1 130 5 doi 10 1016 j jpurol 2013 07 010 PMID 23953243 a b c Barreto L Jung JH Abdelrahim A Ahmed M Dawkins GP Kazmierski M et al Cochrane Urology Group June 2018 Medical and surgical interventions for the treatment of urinary stones in children The Cochrane Database of Systematic Reviews 6 6 CD010784 doi 10 1002 14651858 CD010784 pub2 PMC 6513049 PMID 29859007 Aune D Mahamat Saleh Y Norat T Riboli E November 2018 Body fatness diabetes physical activity and risk of kidney stones a systematic review and meta analysis of cohort studies European Journal of Epidemiology 33 11 1033 1047 doi 10 1007 s10654 018 0426 4 PMC 6208979 PMID 30066054 Trinchieri A Croppi E Montanari E June 2017 Obesity and urolithiasis evidence of regional influences Urolithiasis 45 3 271 278 doi 10 1007 s00240 016 0908 3 PMID 27488444 S2CID 4585476 Zisman AL October 2017 Effectiveness of Treatment Modalities on Kidney Stone Recurrence Clinical Journal of the American Society of Nephrology 12 10 1699 1708 doi 10 2215 cjn 11201016 PMC 5628726 PMID 28830863 Stanford J Charlton K Stefoska Needham A Ibrahim R Lambert K 5 June 2020 The gut microbiota profile of adults with kidney disease and kidney stones a systematic review of the literature BMC Nephrology 21 1 215 doi 10 1186 s12882 020 01805 w ISSN 1471 2369 PMC 7275316 PMID 32503496 Duncan SH Richardson AJ Kaul P Holmes RP Allison MJ Stewart CS 1 August 2002 Oxalobacter formigenes and Its Potential Role in Human Health Applied and Environmental Microbiology 68 8 3841 3847 Bibcode 2002ApEnM 68 3841D doi 10 1128 AEM 68 8 3841 3847 2002 ISSN 0099 2240 PMC 124017 PMID 12147479 Ticinesi A Milani C Guerra A Allegri F Lauretani F Nouvenne A Mancabelli L Lugli GA Turroni F Duranti S Mangifesta M 28 April 2018 Understanding the gut kidney axis in nephrolithiasis an analysis of the gut microbiota composition and functionality of stone formers Gut 67 12 2097 2106 doi 10 1136 gutjnl 2017 315734 ISSN 0017 5749 PMID 29705728 S2CID 14055215 Ramirez J Guarner F Bustos Fernandez L Maruy A Sdepanian VL Cohen H 24 November 2020 Antibiotics as Major Disruptors of Gut Microbiota Frontiers in Cellular and Infection Microbiology 10 572912 doi 10 3389 fcimb 2020 572912 ISSN 2235 2988 PMC 7732679 PMID 33330122 Tasian GE Jemielita T Goldfarb DS Copelovitch L Gerber JS Wu Q Denburg MR 1 June 2018 Oral Antibiotic Exposure and Kidney Stone Disease Journal of the American Society of Nephrology 29 6 1731 1740 doi 10 1681 ASN 2017111213 ISSN 1046 6673 PMC 6054354 PMID 29748329 a b c d e Pugh DG Baird N 27 May 2012 Sheep amp Goat Medicine E Book Elsevier Health Sciences ISBN 978 1 4377 2354 0 Archived from the original on 14 April 2021 Retrieved 17 June 2018 Bushman DH Emerick RJ Embry LB December 1965 Experimentally induced ovine phosphatic urolithiasis relationships involving dietary calcium phosphorus and magnesium The Journal of Nutrition 87 4 499 504 doi 10 1093 jn 87 4 499 PMID 5841867 Stewart SR Emerick RJ Pritchard RH May 1991 Effects of dietary ammonium chloride and variations in calcium to phosphorus ratio on silica urolithiasis in sheep PDF Journal of Animal Science 69 5 2225 9 doi 10 2527 1991 6952225x PMID 1648554 S2CID 10130833 Archived from the original PDF on 2 March 2019 Forman SA Whiting F Connell R May 1959 Silica Urolithiasis In Beef Cattle 3 Chemical and Physical Composition of the Uroliths Canadian Journal of Comparative Medicine and Veterinary Science 23 5 157 62 PMC 1581990 PMID 17649146 Scott D Buchan W May 1988 The effects of feeding pelleted diets made from either coarsely or finely ground hay on phosphorus balance and on the partition of phosphorus excretion between urine and faeces in the sheep Quarterly Journal of Experimental Physiology 73 3 315 22 doi 10 1113 expphysiol 1988 sp003148 PMID 3399614 Bravo D Sauvant D Bogaert C Meschy F 2003 III Quantitative aspects of phosphorus excretion in ruminants PDF Reproduction Nutrition Development 43 3 285 300 doi 10 1051 rnd 2003021 PMID 14620634 Archived PDF from the original on 16 April 2021 Retrieved 29 August 2019 Waltner Toews D and D H Meadows 1980 Case report Urolithiasis in a herd of beef cattle associated with oxalate ingestion Can Vet J 21 61 62 James LF Butcher JE December 1972 Halogeton poisoning of sheep effect of high level oxalate intake Journal of Animal Science 35 6 1233 1238 doi 10 2527 jas1972 3561233x PMID 4647453 a b Kahn CM ed 2005 Merck veterinary manual 9th ed Whitehouse Station Merck amp Co Inc Notes edit Committee to Review Dietary Reference Intakes for Vitamin D and Calcium Institute of Medicine of the National Academies 2011 Ross AC Taylor CL Yaktine AL Del HB eds Dietary Reference Intakes for Calcium and Vitamin D Washington DC The National Academies Press doi 10 17226 13050 ISBN 978 0 309 16394 1 PMID 21796828 S2CID 58721779 Archived from the original on 9 September 2014 Retrieved 21 June 2011 Rao PN Preminger GM Kavanagh JP eds 2011 Urinary Tract Stone Disease 1st ed London Springer Verlag doi 10 1007 978 1 84800 362 0 26 ISBN 978 1 84800 361 3 Reilly RF Perazella MA eds 2005 Nephrology in 30 Days 1st ed New York The McGraw Hill Companies Inc ISBN 978 0 07 143701 1 Archived from the original on 14 April 2021 Retrieved 25 August 2020 Stoller ML Meng MV eds 2007 Urinary stone disease the practical guide to medical and surgical management 1st ed Totowa New Jersey Humana Press ISBN 978 1 59259 972 1 External links edit nbsp Wikimedia Commons has media related to Kidney stones Kidney stone disease at Curlie Information from the European Urological Association Kidney Stone Guide Book Archived 3 August 2020 at the Wayback Machine University of Chicago Kidney Stone Program Retrieved from https en wikipedia org w index php title Kidney stone disease amp oldid 1221251390, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.